WO2008117241A2 - Thiazolidine derivatives as orexin receptor antagonists - Google Patents

Thiazolidine derivatives as orexin receptor antagonists Download PDF

Info

Publication number
WO2008117241A2
WO2008117241A2 PCT/IB2008/051110 IB2008051110W WO2008117241A2 WO 2008117241 A2 WO2008117241 A2 WO 2008117241A2 IB 2008051110 W IB2008051110 W IB 2008051110W WO 2008117241 A2 WO2008117241 A2 WO 2008117241A2
Authority
WO
WIPO (PCT)
Prior art keywords
methyl
carboxylic acid
thiazolidin
carbonyl
ylmethyl
Prior art date
Application number
PCT/IB2008/051110
Other languages
French (fr)
Other versions
WO2008117241A3 (en
Inventor
Hamed Aissaoui
Christoph Boss
Markus Gude
Ralf Koberstein
Thierry Sifferlen
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP08719826A priority Critical patent/EP2125760A2/en
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Priority to BRPI0808504-8A priority patent/BRPI0808504A2/en
Priority to AU2008231441A priority patent/AU2008231441A1/en
Priority to CN2008800096488A priority patent/CN101641342B/en
Priority to MX2009009690A priority patent/MX2009009690A/en
Priority to JP2010500407A priority patent/JP2010522737A/en
Priority to US12/593,095 priority patent/US8236964B2/en
Priority to CA002677991A priority patent/CA2677991A1/en
Publication of WO2008117241A2 publication Critical patent/WO2008117241A2/en
Publication of WO2008117241A3 publication Critical patent/WO2008117241A3/en
Priority to IL201112A priority patent/IL201112A0/en
Priority to MA32243A priority patent/MA31289B1/en
Priority to NO20093200A priority patent/NO20093200L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel thiazolidine derivatives of formula (I) and their use as pharmaceuticals.
  • the invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as orexin receptor antagonists.
  • Orexins are novel neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to G-protein-coupled receptors (OXi and OX 2 receptors).
  • the orexin-1 receptor (OXi) is selective for OX-A
  • the orexin-2 receptor (OX 2 ) is capable to bind OX-A as well as OX-B.
  • Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et ai., Cell, 1998, 92, 573-585). On the other hand, it was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to narcolepsy as well as insomnia and other sleep disorders (Chemelli R. M. et ai., Cell, 1999, 98, 437-451 ). Orexin receptors are found in the mammalian brain and may have numerous implications in pathologies as known from the literature.
  • the present invention provides thiazolidine derivatives, which are non-peptide antagonists of human orexin receptors. These compounds are in particular of potential use in the treatment of e.g. eating disorders, drinking disorders, sleep disorders, or cognitive dysfunctions in psychiatric and neurologic disorders.
  • Piperidine derivatives useful as orexin receptor antagonists are disclosed in WO01/96302.
  • Morpholine derivatives useful as orexin receptor antagonists are disclosed in WO02/44172.
  • ⁇ /-Aroyl cyclic amine derivatives useful as orexin receptor antagonists are disclosed in WO02/90355.
  • a first aspect of the invention consists of a compound of the formula (I)
  • A represents
  • X represents O, or S;
  • R 2 represents (d- 4 )alkyl;
  • D represents aryl, which is unsubstituted, mono-, di, or tri-substituted wherein the substituents are independently selected from the group consisting of (Ci- 4 )alkyl, (Ci- 4 )alkoxy, trifluoromethyl, and halogen;
  • R 1 represents aryl, wherein the aryl group is selected from the group consisting of a phenyl-, a naphthyl-, a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro- benzo[1 ,4]dioxinyl-, a 4/-/-benzo[1 ,3]dioxinyl, a 2/-/-chromenyl-, a chromanyl-, a 3,4- dihydro-2/-/-benzo[1 ,4]oxazinyl-, and a 3-biphenyl group, wherein said groups are unsubstituted, mono-, di, or tri-substituted wherein the substituents are independently selected from the group consisting of (Ci_ 4 )alkyl, (Ci.
  • R 1 represents heteroaryl, which is unsubstituted, mono-, di, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci- 4 )alkyl, (Ci- 4 )alkoxy, halogen, hydroxy-(Ci- 4 )alkyl, and trifluoromethyl.
  • halogen means fluorine, chlorine, or bromine, preferably fluorine or chlorine.
  • (Ci- 4 )alkyl means a straight-chain or branched-chain alkyl group with 1 to 4 carbon atoms.
  • Examples of (Ci- 4 )alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert.-butyl. Preferred are methyl and ethyl. Most preferred is methyl.
  • (d- 4 )alkoxy means a group of the formula (d- 4 )alkyl-O- in which the term "(Ci -4 )alkyl" has the previously given significance.
  • Examples of (d- 4 )alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.- butoxy. Preferred are methoxy and ethoxy. Most preferred is methoxy.
  • D representing "aryl” means unsubstituted, mono-, di-, or tri-substituted naphthyl or (preferably) phenyl (preferred mono- or di-substituted phenyl), wherein the substituents are independently selected from the group consisting of (d- 4 )alkyl, (d- 4 )alkoxy, trifluoromethyl, and halogen; most preferably from (d_ 4 )alkyl, (d_ 4 )alkoxy and halogen.
  • Examples of "D” representing "aryl” are phenyl, 3-methylphenyl, 4-methylphenyl, 3,4- dimethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3- trifluoromethylphenyl and 4-trifluoromethylphenyl.
  • R 1 representing "aryl” means a group selected from the group consisting of a phenyl, a naphthyl, a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro- benzo[1 ,4]dioxinyl-, a 4/-/-benzo[1 ,3]dioxinyl, a 2/-/-chromenyl-, a chromanyl-, or a 3,4- dihydro-2/-/-benzo[1 ,4]oxazinyl, and a 3-biphenyl-group.
  • R 1 The above mentioned aryl group as used for "R 1 " is unsubstituted, mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (d_ 4 )alkyl, (d- 4 )alkoxy, trifluoromethyl, halogen and nitro; preferably from (d- 4 )alkyl, (d- 4 )alkoxy, trifluoromethyl, and halogen; most preferably from (d_ 4 )alkyl, (d_ 4 )alkoxy and halogen.
  • R 1 " representing "aryl” means a naphthyl- or (preferably) a phenyl group, which group is unsubstituted, mono-, di-, or tri-substituted (preferred: monosubstituted), wherein the substituents are independently selected from the group consisting of (d_ 4 )alkyl, (d_ 4 )alkoxy, trifluoromethyl, halogen and nitro; especially from (d- 4 )alkyl, (d- 4 )alkoxy, halogen, and trifluoromethyl (preferred: halogen).
  • R 1 " representing "aryl” means a 2,3-dihydro-benzofuranyl- ; a benzo[1 ,3]dioxolyl-; a 2,3-dihydro-benzo[1 ,4]dioxinyl-; a 4H-benzo[1 ,3]dioxinyl-, a 2/-/-chromenyl-, a chromanyl-, or a 3,4-dihydro-2/-/-benzo[1 ,4]oxazinyl group (especially a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, or a 4H-benzo[1 ,3]dioxinyl group).
  • Said aryl groups of this sub-embodiment are unsubstituted, mono-, di-, or tri-substituted (preferred unsubstituted, mono- or di- substituted) wherein the substituents are independently selected from the group consisting of (d_ 4 )alkyl, (d_ 4 )alkoxy, trifluoromethyl, and halogen; preferred from (d- 4 )alkyl, (d- 4 )alkoxy and halogen.
  • 2,3-dihydro- benzofuranyl-, benzo[1 ,3]dioxolyl-, 2,3-dihydro-benzo[1 ,4]dioxinyl-, AH- benzo[1 ,3]dioxinyl-, 2/-/-chromenyl-, chromanyl-, and 3-biphenyl groups are preferably unsubstituted.
  • 3,4-Dihydro-2H-benzo[1 ,4]oxazinyl groups are preferably unsubstituted or mono-substituted with (d- 4 )alkyl (especially methyl).
  • a 2,3-dihydro-benzofuranyl group may also be disubstituted, wherein the substituents are independently selected from halogen and (d- 4 )alkoxy.
  • R 1 representing "aryl" are naphthyl, 3-bromophenyl, 3-nitrophenyl, 3- biphenyl, 2,3-dihydro-benzofuran-4-yl, 2,3-dihydro-benzofuran-7-yl, 7-chloro-2- methoxy-2,3-dihydro-benzofuran-4-yl, 4H-benzo[1 ,3]dioxin-5-yl, 4H-benzo[1 ,3]dioxin-8- yl, benzo[1 ,3]dioxol-4-yl, 2,3-dihydro-benzo[1 ,4]dioxin-5-yl, chromen-5-yl, chroman-5- yl, chroman-8-yl, 3,4-dihydro-2/-/-benzo[1 ,4]oxazin-5-yl, 4-methyl-3,4-dihydro-2H- benzo[1 ,
  • preferred examples of R 1 representing "aryl" are 2,3-dihydro-benzo[1
  • heteroaryl means a 5- to 10-membered monocyclic or bicyclic (preferred 8- to 9-membered bicyclic) aromatic ring containing 1 , 2 or 3 heteroatoms, each independently selected from oxygen, nitrogen and sulfur.
  • heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl,
  • further examples are benzoisothiazolyl, and pyrrolo[2,1 -b]thiazolyl.
  • Preferred examples are thienyl, thiazolyl, pyrazolyl, pyridyl, indolyl, benzofuranyl, indazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoxadiazolyl, benzothiadiazolyl, imidazo[1 ,2- a]pyridyl, imidazo[2,1 -b]thiazolyl, benzoisothiazolyl, and pyrrolo[2,1 -b]thiazolyl.
  • preferred examples are benzisoxazolyl, benzoxadiazolyl, benzothiadiazolyl, imidazo[1 ,2-a]pyridyl, imidazo[2,1 -b]thiazolyl, benzoisothiazolyl, and pyrrolo[2,1 -b]thiazolyl.
  • heteroaryl groups are unsubstituted, mono-, di-, or tri-substituted (preferred unsubstituted, mono-, or di-substituted) wherein the substituents are independently selected from the group consisting of (d- 4 )alkyl, (d- 4 )alkoxy, halogen, hydroxy-(d- 4 )alkyl, and trifluoromethyl; especially from (d- 4 )alkyl, (Ci -4 )alkoxy, halogen, and trifluoromethyl; preferred from (Ci -4 )alkyl, halogen, and trifluoromethyl.
  • heteroaryl groups are thienyl, pyridyl, indolyl, indazolyl, benzofuranyl, and imidazo[2,1 -b]thiazolyl, which groups may be unsubstituted, mono-, di-, or tri-substituted (preferred unsubstituted, mono-, or di-substituted, most preferred unsubstituted, or mono-substituted) wherein the substituents are independently selected from the group consisting of (Ci- 4 )alkyl, (d- 4 )alkoxy, halogen, and trifluoromethyl (preferred (C 1-4 )alkyl, and halogen).
  • heteroaryl groups as used for the substituent "R 1 " are preferably substituted as follows: thienyl groups are substituted with halogen; thiazolyl groups are di-substituted with (C 1 -4 )alkyl; pyrazolyl groups are di-substituted with (C 1-4 )alkyl; pyridyl groups are mono-substituted with halogen; indolyl groups are mono-substituted with (Ci -4 )alkyl (especially methyl); indazolyl groups are unsubstituted or mono-substituted with (Ci -4 )alkyl (especially methyl); benzoxazolyl groups are unsubstituted, or mono-substituted with (Ci -4 )alkyl (especially methyl); benzothiazolyl groups are unsubstituted or mono-substituted with halogen; benzisox
  • benzofuranyl groups are benzofuran-4- yl, 7-chloro-benzofuran-4-yl, 7-fluoro-benzofuran-4-yl, 2-fluoro-benzofuran-4-yl, 3- methyl-benzofuran-4-yl, 2-methyl-benzofuran-4-yl, 2-hydroxymethyl-benzofuran-4-yl, 5- chloro-2-methyl-benzofuran-4-yl, 7-chloro-2-methyl-benzofuran-4-yl, 7-fluoro-2-methyl- benzofuran-4-yl, 6-chloro-2-methyl-benzofuran-4-yl, 6-fluoro-2-methyl-benzofuran-4-yl, 2,3-dimethyl-benzofuran-4-yl, 2-trifluoromethyl-benzofuran-4-yl, 7-trifluoromethyl- benzofuran-4-yl, 2-methyl-6-trifluoromethyl-benzofuran-4-yl
  • a further embodiment of the invention relates to thiazolidine derivatives of formula (I) according to embodiment i), wherein the stereogenic center at the thiazolidine ring is in (R)-configuration.
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) or ii), wherein A represents
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to iii), wherein A represents
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to iv), wherein X represents S. vi) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to iv), wherein X represents O. vii) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to vi), wherein R 2 represents methyl. viii) A further embodiment of the invention relates to thiazolidine derivatives according to embodiments i) or ii), wherein A represents
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to viii), wherein D represents unsubstituted, mono-, di-, or tri-substituted phenyl, wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (Ci -4 )alkoxy, trifluoromethyl, and halogen.
  • D represents unsubstituted, mono-, di-, or tri-substituted phenyl, wherein the substituents are independently selected from the group consisting of (C 1-4 )alkyl, (Ci -4 )alkoxy, trifluoromethyl, and halogen.
  • R 1 represents aryl, wherein the aryl group is selected from the group consisting of a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, a 4/-/-benzo[1 ,3]dioxinyl, a 2/-/-chromenyl-, a chromanyl-, and a 3,4-dihydro-2H- benzo[1 ,4]oxazinyl group, wherein said groups are unsubstituted, mono-, or di- substituted wherein the substituents are independently selected from the group consisting of (d- 4 )alkyl, (d- 4 )alkoxy and halogen; or R 1 represents heteroaryl, which is unsubstituted, mono-, di, or tri-substituted, wherein the substituents are
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to x), wherein R 1 represents heteroaryl, wherein said hetereroaryl is selected from the group consisting of thienyl, thiazolyl, pyrazolyl, pyridyl, indolyl, benzofuranyl, indazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoxadiazolyl, benzothiadiazolyl, imidazo[1 ,2-a]pyridyl, imidazo[2,1 -b]thiazolyl, benzoisothiazolyl, and pyrrolo[2,1 -b]thiazolyl, wherein said groups are unsubstituted, mono-, di-, or tri-substi
  • xii) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to x), wherein R 1 represents heteroaryl, wherein said hetereroaryl is selected from the group consisting of benzisoxazolyl, benzoxadiazolyl, benzothiadiazolyl, imidazo[1 ,2-a]pyridyl, imidazo[2,1 -b]thiazolyl, benzoisothiazolyl, and pyrrolo[2,1 -b]thiazolyl, wherein said groups are unsubstituted, mono-, or di-substituted wherein the substituents are independently selected from the group consisting of (Ci -4 )alkyl, (Ci -4 )alkoxy, halogen, and trifluoromethyl.
  • R 1 represents heteroaryl, wherein said hetereroaryl is selected from the group consisting of benzisoxazolyl, benzox
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to xi), wherein R 1 represents heteroaryl, wherein said hetereroaryl is selected from the group consisting of thienyl, pyridyl, indolyl, benzofuranyl, indazolyl, and imidazo[2,1 -b]thiazolyl, wherein said groups are unsubstituted, mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (d- 4 )alkyl, (d- 4 )alkoxy, halogen, and trifluoromethyl.
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to ix), wherein R 1 represents a naphthyl- or a phenyl group (preferred) which is unsubstituted, mono-, di-, or tri-substituted (preferred: mono- substituted), wherein the substituents are independently selected from the group consisting of (Ci- 4 )alkyl, (Ci_ 4 )alkoxy, trifluoromethyl, halogen and nitro (especially from (Ci- 4 )alkyl, (Ci- 4 )alkoxy, halogen, and trifluoromethyl (preferred: halogen)).
  • R 1 represents a naphthyl- or a phenyl group (preferred) which is unsubstituted, mono-, di-, or tri-substituted (preferred: mono- substituted), wherein the substituents are independently selected from the group consisting of (C
  • R 1 represents aryl, wherein the aryl group is selected from the group consisting of a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, a 4/-/-benzo[1 ,3]dioxinyl, a 2/-/-chromenyl-, a chromanyl-, and a 3,4-dihydro-2H- benzo[1 ,4]oxazinyl group, wherein said groups are unsubstituted, mono-, or di- substituted wherein the substituents are independently selected from the group consisting of (d- 4 )alkyl, (d- 4 )alkoxy and halogen.
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to x) or xvi), wherein, in case R 1 represents an aryl group, said aryl group is selected from the group consisting of a 2,3-dihydro-benzofuranyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, a chromanyl-, and a 3,4-dihydro-2H-benzo[1 ,4]oxazinyl group, wherein said groups are unsubstituted, mono-, or di-substituted wherein the substituents are independently selected from the group consisting of (d- 4 )alkyl, (Ci_ 4 )alkoxy and halogen.
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to x), or xvi), wherein, in case R 1 represents an aryl group, said aryl group is selected from the group consisting of a 2,3-dihydro- benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, or a AH- benzo[1 ,3]dioxinyl group, wherein said groups are unsubstituted.
  • R 1 represents a group selected from
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to xi), wherein R 1 represents a group selected from
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to xi), wherein R 1 represents a group selected from xxii)
  • a further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to xi) or xxi), wherein R 1 represents
  • a further embodiment of the invention relates to thiazolidine derivatives of formula (I) according to embodiments i) or ii) wherein A represents
  • X represents S, or O;
  • D represents unsubstituted, mono-, or di-substituted phenyl, wherein the substituents are independently selected from the group consisting of (C 1 -4 )alkyl, (Ci -4 )alkoxy, trifluoromethyl, and halogen; and
  • R 1 represents a group selected from 2,3-dihydro-benzofuran-4-yl, 2,3-dihydro- benzofuran-7-yl, 7-chloro-2-methoxy-2,3-dihydro-benzofuran-4-yl, 2,3-dihydro- benzo[1 ,4]dioxin-5-yl, chroman-5-yl, chroman-8-yl, 3,4-dihydro-2/-/-benzo[1 ,4]oxazin-5- yl, 4-methyl-3,4-dihydro-2H-benzo[1 ,4]oxazine-5-yl, 3,4-dihydro-2H-benzo[1 ,4]oxazin- 8-yl, and 4-methyl-3,4-dihydro-2H-benzo[1 ,4]oxazine-8-yl; or R 1 represents a group selected from 2,3-dihydro-benzofuran-4
  • R 1 represents phenyl which is mono-substituted with halogen or nitro, naphthyl, pyridyl which is mono-substituted with halogen, thienyl which is mono-substituted with halogen, thiazolyl which is disubstituted with (C 1-4 )alkyl, or pyrazolyl which is disubstituted with (d- 4 )alkyl (especially R 1 represents
  • phenyl which is mono-substituted with halogen, pyridyl which is mono-substituted with halogen, or thienyl which is mono-substituted with halogen).
  • the compounds of formula (I) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. Substituents at a double bond may be present in the Z- or E-configuration unless indicated otherwise.
  • the compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
  • salts refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201 -217.
  • Examples of preferred compounds of formula (I) according to embodiment i) are selected from the group consisting of:
  • 6-Bromo-pyridine-2-carboxylic acid ⁇ (R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl ⁇ -amide;
  • preferred compounds of formula (I) according to embodiment i) are selected from the group consisting of: Naphthalene-1 -carboxylic acid ⁇ (R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl ⁇ -amide;
  • Benzothiazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide; Benzothiazole-7-carboxylic acid ⁇ (R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl ⁇ -amide;
  • Benzothiazole-4-carboxylic acid ⁇ (R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl ⁇ -amide; Benzo[2,1 ,3]thiadiazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
  • 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid ⁇ (R)-3-[5-(4-fluoro-phenyl)-2-methyl- oxazole-4-carbonyl]-thiazolidin-4-ylmethyl ⁇ -amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(2-methyl-4-p-tolyl-thiazole-5- carbonyl)-thiazolidin-4-ylmethyl]-amide; ⁇ -Methyl-imidazo ⁇ J -blthiazole-S-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-oxazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
  • the compounds of formula (I) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral or parenteral administration.
  • compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21 st Edition (2005), Part 5, "Pharmaceutical Manufacturing” [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
  • the present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I).
  • the compounds according to formula (I) may be used for the preparation of a medicament and are suitable for the prevention or treatment of diseases selected from the group consisting of dysthymic disorders including major depression and cyclothymia, affective neurosis, all types of manic depressive disorders, delirium, psychotic disorders, schizophrenia, catatonic schizophrenia, delusional paranoia, adjustment disorders and all clusters of personality disorders; schizoaffective disorders; anxiety disorders including generalized anxiety, obsessive compulsive disorder, posttraumatic stress disorder, panic attacks, all types of phobic anxiety and avoidance; separation anxiety; all psychoactive substance use, abuse, seeking and reinstatement; all types of psychological or physical addictions, dissociative disorders including multiple personality syndromes and psychogenic amnesias; sexual and reproductive dysfunction; psychosexual dysfunction and addiction; tolerance to narcotics or withdrawal from narcotics; increased anaesthetic risk, anaesthetic responsiveness; hypothalamic-adrenal dysfunctions; disturbed biological and circadian rhythms; sleep disturbances
  • Compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of psychoactive substance use and abuse, of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders.
  • Eating disorders may be defined as comprising metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa.
  • Pathologically modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs. expenditure); disturbed perception of food quality (high fat or carbohydrates, high palatability); disturbed food availability (unrestricted diet or deprivation) or disrupted water balance.
  • Drinking disorders include polydipsias in psychiatric disorders and all other types of excessive fluid intake.
  • Sleep disorders include all types of parasomnias, insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders.
  • Insomnias are defined as comprising sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new environment, noise) or short-term insomnia due to stress; grief; pain or illness.
  • Insomnia also include stress-related syndromes including post-traumatic stress disorders as well as other types and subtypes of anxiety disorders such as generalized anxiety, obsessive compulsive disorder, panic attacks and all types of phobic anxiety and avoidance; psychoactive substance use, abuse, seeking and reinstatement are defined as all types of psychological or physical addictions and their related tolerance and dependence components.
  • Cognitive dysfunctions include deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.
  • compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of sleep disorders that comprises all types of insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders.
  • sleep disorders that comprises all types of insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders.
  • compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of cognitive dysfunctions that comprise deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.
  • compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of eating disorders that comprise metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa.
  • compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of psychoactive substance use and abuse that comprise all types of psychological or physical addictions and their related tolerance and dependence components.
  • a further aspect of the invention is a process for the preparation of compounds of formula (I).
  • Compounds according to formula (I) of the present invention can be prepared according to the general sequence of reactions outlined in the schemes below wherein A, D, X, R 1 and R 2 are as defined for formula (I).
  • the compounds obtained may also be converted into pharmaceutically acceptable salts thereof in a manner known per se.
  • Thiazolidine derivatives of formula (I) may be prepared by reacting a thiazolidine derivative of structure (3) with an acid of the general formula A-COOH in a polar aprotic solvent such as DMF, THF, DCM at RT in the presence of a coupling reagent such as TBTU, EDC/HOAt, HATU in the presence of a base such as TEA, DIPEA, DMAP.
  • a coupling reagent such as TBTU, EDC/HOAt, HATU in the presence of a base such as TEA, DIPEA, DMAP.
  • Acids of the general formula A-COOH are commercially available or synthesized according to methods described below.
  • Thiazolidine derivates of structure (3) may be prepared by treatment of compounds of structure (2) with acids such as HCI in dioxane, TFA in DCM, neat TFA at RT.
  • Compounds of structure (3) may be used as free base or salts thereof such as the hydrochloride salt.
  • a compound of structure (2) may be prepared by reacting 4-aminomethyl-thiazolidine- 3-carboxylic acid tert-butyl ester of structure (1 ), which is commercially available, with an acid of the general formula R 1 -COOH in a polar aprotic solvent such as DMF, THF, DCM at RT in the presence of a coupling reagent such as TBTU, EDC, HATU in presence or absence of additives such as HOBt, HOAt in the presence of a base such as TEA, DIPEA, DMAP.
  • Acids of the general formula R 1 COOH are commercially available, or synthesized according to methods described below. Preparation of carboxylic acids A-COOH
  • Carboxylic acid derivatives A-COOH wherein A represents a thiazole-4-yl derivative are commercially available or can be synthesised according to scheme 2.
  • the 2-acetamido-3-oxo-propionic acid ester derivative (15) can be synthesized from compounds of structure (14) using acetic anhydride in presence of an acid such as glacial acetic acid and catalytic amounts of metal chlorides such as mercury chloride and zinc powder.
  • Cyclization to the corresponding corresponding oxazole-4 carboxylic acid ester derivative (16) can be achieved under dehydrating conditions such as thionyl chloride in chloroform. Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in solvent mixtures such as ethanol/water provides the corresponding oxazole-4 carboxylic acid derivative (17).
  • Carboxylic acid derivatives A-COOH wherein A represents a phenyl-2-yl derivative are commercially available or can be synthesised according to scheme 5.
  • Carboxylic acids of formula R 1 -COOH are commercially available or well known in the art (Lit. e.g. WO2001/96302; T. Eicher, S. Hauptmann "The chemistry of Heterocycles: Structure, Reactions, Syntheses, and Applications", 2nd Edition 2003, Wiley, ISBN 978-3-527-30720-3).
  • Carboxylic acid derivatives R 1 -COOH which represent an imidazo[2,1 -b]thiazole- 2-carboxylic acid derivative are commercially available or can be synthesised according to scheme 6.
  • Pathway A By reaction of 2-chloro-3-oxo-butyric acid methyl ester (20) with thiourea the amino-thiazole (21 ) can be obtained. Transformation to ester (22) can be accomplished with bromoacetaldehydewhich can be generated in-situ from bromoacetaldehyde diethylacetal under acidic conditions. After saponification with bases such as sodium hydroxide the desired acid (23) can be obtained.
  • Carboxylic acid derivatives R 1 -COOH which represent a pyrrolo[2,1 -£>]thiazole- 7-carboxylic acid derivative can be synthesised according to scheme 7
  • EtOH/ water provides the corresponding pyrrolo[2,1 -£>]thiazole-7-carboxylic acid derivative (31 ) (Berry CR. et al., Organic Letters, 2007, 9, 21 , 4099-4102).
  • Carboxylic acid derivatives R 1 -COOH which represent a 3,4-dihydro-2H- benzo[1 ,4]oxazinyl- or 3-oxo-3,4-dihydro-2/-/-benzo[1 ,4]oxazinyl-carboxylic acid derivative can be synthesised according to the literature according to schemes 8 and 9.
  • Carboxylic acid derivatives R 1 -COOH which represent a benzooxazole-4-carboxylic acid derivative can be synthesised according to the literature according to schemes 10 and 1 1 .
  • ester (48) By cyclisation of ethyl 2-amino-3-hydroxybenzoate (47) with acetyl chloride in the presence of PPTS and TEA, the ester (48) can be obtained (Goldstein S.W. et al, Journal of Heterocyclic Chemistry, 1990, 27, 335-336). Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in a solvent such as EtOH / water provides the corresponding 2-methyl-benzooxazole- 4-carboxylic acid derivative (49).
  • the benzooxazole-7-carboxylic acid (51 ) can be obtained (WO2006/069155).
  • the 2-methyl-benzooxazole-7-carboxylic acid (52) can be obtained (WO2006/069155)
  • Carboxylic acid derivatives R 1 -COOH which represent a benzothiazole-7-carboxylic acid derivative can be synthesised according to the literature according to scheme " ! 2.
  • Carboxylic acid derivatives R 1 -COOH which represent a benzofuran-4-carboxylic acid derivative can be synthesised according to the literature according to schemes 13 and 14.
  • the ester (59) By reaction of methyl 3-hydroxybenzoate (58) with 3-chloro-2-butanone, the ester (59) can be obtained. Cyclisation with sulfuric acid provides the 2,3-dimethyl-benzofurane derivative (60) (Kawase Y. et al, Bulletin of the Chemical Sociaty of Japan, 1967, 40, 5, 1224-1231 ). Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in a solvent such as MeOH/ water provides the corresponding 2,3-dimethyl-benzofuran-4-carboxylic acid derivative (61 ).
  • the alkyl-ether derivative (70) By esterification of phenol derivative (69) with EtOH in the presence of an acid such as sulfuric acid followed by alkylation by reaction with allyl bromide in the presence of a K 2 CO 3 and Kl, the alkyl-ether derivative (70) can be obtained. Claisen rearrangement by reaction with N,N-dimethylaniline furnishes the phenol derivative (71 ). Ozonolysis followed by reaction with PTSA provides the benzofurane derivative (72). On the other hand ozonolysis of (71 ) in the presence of MeOH furnishes the dihydro-benzofurane derivative (74).
  • Carboxylic acid derivatives R 1 -COOH which represent a benzofuran-4-carboxylic acid derivative can be synthesised according to the literature according to scheme 16.
  • Carboxylic acid derivatives R 1 -COOH which represent a 2-fluorobenzofuran-4- carboxylic acid derivative can be synthesised according to the literature according to scheme 17.
  • N-acyl-thiazolidine derivatives (86) can be prepared by trifluoroacetylation of commercially available (R)-4-Aminomethyl-thiazolidine-3- carboxylic acid tert-butyl ester (85) with ethyl trifluoroacetate followed by removal of the Boc-protecting group with TFA, acylation with A-CO 2 H using classical amide coupling methodology (TBTU/ DIPEA) and finally removal of the trifluoroacetyl-protecting group by reaction with sat. K 2 CO 3 .
  • the enantiomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Regis Whelk-O1 (R,R) (10 ⁇ m) column, a Daicel ChiralCel OD-H (5-10 ⁇ m) column, or a Daicel ChiralPak IA (10 ⁇ m) or AD-H (5 ⁇ m) column.
  • a chiral stationary phase such as a Regis Whelk-O1 (R,R) (10 ⁇ m) column, a Daicel ChiralCel OD-H (5-10 ⁇ m) column, or a Daicel ChiralPak IA (10 ⁇ m) or AD-H (5 ⁇ m) column.
  • Typical conditions of chiral HPLC are an isocratic mixture of eluent A (ethanol, in presence or absence of an amine such as TEA, diethylamine) and eluent B (hexane), at a flow rate of 0.8 to 150 mL/min.
  • eluent A ethanol, in presence or absence of an amine such as TEA, diethylamine
  • eluent B hexane
  • FCS Foatal calf serum
  • 3-Chloro-2-oxo-3-p-tolyl-propionic acid methyl ester prepared by reaction of 4-methyl-benzaldehyde with methyl dichloroacetate.
  • 3-Chloro-3-(3-fluoro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3-fluoro-benzaldehyde with methyl dichloroacetate.
  • 3-Chloro-3-(2-fluoro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 2-fluoro-benzaldehyde with methyl dichloroacetate.
  • 3-Chloro-3-(4-methoxy-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 4-methoxy-benzaldehyde with methyl dichloroacetate.
  • 2-Acetylamino-3-oxo-3-p-tolyl-propionic acid methyl ester prepared according to general procedure A.2.1 from 3-oxo-3-p-tolyl-propionic acid methyl ester.
  • 2-Acetylamino-3-(4-fluoro-phenyl)-3-oxo-propionic acid methyl ester prepared according to general procedure A.2.1 from 3-oxo-3-(4-fluoro-phenyl)- propionic acid methyl ester.
  • Biphenyl-2-carboxylic acid 4'-Methyl-biphenyl-2-carboxylic acid; 3'-Methyl-biphenyl-2-carboxylic acid;
  • the orexin receptor antagonistic activity of the compounds of formula (I) is determined in accordance with the following experimental method.
  • Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 ⁇ g/ml G418, 100 U/ml penicillin, 100 ⁇ g/ml streptomycin and 10 % inactivated fetal calf serum (FCS).
  • FCS fetal calf serum
  • the cells are seeded at 80'0OO cells / well into 96-well black clear bottom sterile plates (Costar) which have been precoated with 1 % gelatine in Hanks' Balanced Salt Solution (HBSS). All reagents are from Gibco BRL.
  • the seeded plates are incubated overnight at 37°C in 5% CO 2 .
  • Human orexin-A as an agonist is prepared as 1 mM stock solution in methanol: water (1 :1 ), diluted in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES for use in the assay at a final concentration of 10 nM.
  • BSA bovine serum albumin
  • Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 96-well plates, first in DMSO, then in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES.
  • BSA bovine serum albumin
  • the 96-well plates are incubated for 60 min at 37° C in 5% CO 2 .
  • the loading solution is then aspirated and cells are washed 3 times with 200 ⁇ l HBSS containing 2.5 mM probenecid, 0.1% BSA, 2 mM HEPES. 100 ⁇ l of that same buffer is left in each well.
  • Within the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices) antagonists are added to the plate in a volume of 50 ⁇ l, incubated for 20 min and finally 100 ⁇ l of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by 10 nM orexin-A with buffer in place of antagonist.
  • IC 50 value the concentration of compound needed to inhibit 50 % of the agonistic response
  • Antagonistic activities of compounds are in the nanomolar range below 1000 nM with respect to the OXi and/or the OX 2 receptor.
  • Antagonistic activities (IC 50 values) of 162 exemplified compounds are in the range of 0.9 - 7245 nM with an average of 181 nM with respect to the 0X1 receptor.
  • IC 50 values of 164 exemplified compounds are in the range of 0.7-1285 nM with an average of 96 nM with respect to the 0X2 receptor.
  • Antagonistic activities of selected compounds are displayed in Table 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)

Abstract

The invention relates to novel thiazolidine derivatives of the formula (I) wherein A and R1 are as described in the description and their use as medicaments, especially as orexin receptor antagonists.

Description

Thiazolidine derivatives
The present invention relates to novel thiazolidine derivatives of formula (I) and their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of formula (I), and especially their use as orexin receptor antagonists.
Orexins (orexin A or OX-A and orexin B or OX-B) are novel neuropeptides found in 1998 by two research groups, orexin A is a 33 amino acid peptide and orexin B is a 28 amino acid peptide (Sakurai T. et al., Cell, 1998, 92, 573-585). Orexins are produced in discrete neurons of the lateral hypothalamus and bind to G-protein-coupled receptors (OXi and OX2 receptors). The orexin-1 receptor (OXi) is selective for OX-A, and the orexin-2 receptor (OX2) is capable to bind OX-A as well as OX-B. Orexins are found to stimulate food consumption in rats suggesting a physiological role for these peptides as mediators in the central feedback mechanism that regulates feeding behaviour (Sakurai T. et ai., Cell, 1998, 92, 573-585). On the other hand, it was also observed that orexins regulate states of sleep and wakefulness opening potentially novel therapeutic approaches to narcolepsy as well as insomnia and other sleep disorders (Chemelli R. M. et ai., Cell, 1999, 98, 437-451 ). Orexin receptors are found in the mammalian brain and may have numerous implications in pathologies as known from the literature.
The present invention provides thiazolidine derivatives, which are non-peptide antagonists of human orexin receptors. These compounds are in particular of potential use in the treatment of e.g. eating disorders, drinking disorders, sleep disorders, or cognitive dysfunctions in psychiatric and neurologic disorders.
Up to now, several low molecular weight compounds are known having a potential to antagonise either specifically OXi or OX2, or both receptors at the same time. Piperidine derivatives useful as orexin receptor antagonists are disclosed in WO01/96302. Morpholine derivatives useful as orexin receptor antagonists are disclosed in WO02/44172. Λ/-Aroyl cyclic amine derivatives useful as orexin receptor antagonists are disclosed in WO02/90355.
The present invention describes for the first time thiazolidine derivatives as orexin receptor antagonists. i) A first aspect of the invention consists of a compound of the formula (I)
Figure imgf000003_0001
(I) wherein
A represents
Figure imgf000003_0002
X represents O, or S; R2 represents (d-4)alkyl;
D represents aryl, which is unsubstituted, mono-, di, or tri-substituted wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, trifluoromethyl, and halogen;
R1 represents aryl, wherein the aryl group is selected from the group consisting of a phenyl-, a naphthyl-, a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro- benzo[1 ,4]dioxinyl-, a 4/-/-benzo[1 ,3]dioxinyl, a 2/-/-chromenyl-, a chromanyl-, a 3,4- dihydro-2/-/-benzo[1 ,4]oxazinyl-, and a 3-biphenyl group, wherein said groups are unsubstituted, mono-, di, or tri-substituted wherein the substituents are independently selected from the group consisting of (Ci_4)alkyl, (Ci.4)alkoxy, trifluoromethyl, halogen and nitro; or R1 represents heteroaryl, which is unsubstituted, mono-, di, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci- 4)alkyl, (Ci-4)alkoxy, halogen, hydroxy-(Ci-4)alkyl, and trifluoromethyl.
The term "halogen" means fluorine, chlorine, or bromine, preferably fluorine or chlorine.
The term "(Ci-4)alkyl" means a straight-chain or branched-chain alkyl group with 1 to 4 carbon atoms. Examples of (Ci-4)alkyl groups are methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tert.-butyl. Preferred are methyl and ethyl. Most preferred is methyl. The term "(d-4)alkoxy" means a group of the formula (d-4)alkyl-O- in which the term "(Ci-4)alkyl" has the previously given significance. Examples of (d-4)alkoxy groups are methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec.-butoxy and tert.- butoxy. Preferred are methoxy and ethoxy. Most preferred is methoxy. "D" representing "aryl" means unsubstituted, mono-, di-, or tri-substituted naphthyl or (preferably) phenyl (preferred mono- or di-substituted phenyl), wherein the substituents are independently selected from the group consisting of (d-4)alkyl, (d-4)alkoxy, trifluoromethyl, and halogen; most preferably from (d_4)alkyl, (d_4)alkoxy and halogen. Examples of "D" representing "aryl" are phenyl, 3-methylphenyl, 4-methylphenyl, 3,4- dimethylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-difluorophenyl, 3,4-dichlorophenyl, 3- trifluoromethylphenyl and 4-trifluoromethylphenyl.
"R1" representing "aryl" means a group selected from the group consisting of a phenyl, a naphthyl, a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro- benzo[1 ,4]dioxinyl-, a 4/-/-benzo[1 ,3]dioxinyl, a 2/-/-chromenyl-, a chromanyl-, or a 3,4- dihydro-2/-/-benzo[1 ,4]oxazinyl, and a 3-biphenyl-group. The above mentioned aryl group as used for "R1" is unsubstituted, mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (d_4)alkyl, (d- 4)alkoxy, trifluoromethyl, halogen and nitro; preferably from (d-4)alkyl, (d-4)alkoxy, trifluoromethyl, and halogen; most preferably from (d_4)alkyl, (d_4)alkoxy and halogen. In one sub-embodiment, "R1" representing "aryl" means a naphthyl- or (preferably) a phenyl group, which group is unsubstituted, mono-, di-, or tri-substituted (preferred: monosubstituted), wherein the substituents are independently selected from the group consisting of (d_4)alkyl, (d_4)alkoxy, trifluoromethyl, halogen and nitro; especially from (d-4)alkyl, (d-4)alkoxy, halogen, and trifluoromethyl (preferred: halogen). Additionally, in another sub-embodiment "R1" representing "aryl" means a 2,3-dihydro-benzofuranyl- ; a benzo[1 ,3]dioxolyl-; a 2,3-dihydro-benzo[1 ,4]dioxinyl-; a 4H-benzo[1 ,3]dioxinyl-, a 2/-/-chromenyl-, a chromanyl-, or a 3,4-dihydro-2/-/-benzo[1 ,4]oxazinyl group (especially a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, or a 4H-benzo[1 ,3]dioxinyl group). Said aryl groups of this sub-embodiment are unsubstituted, mono-, di-, or tri-substituted (preferred unsubstituted, mono- or di- substituted) wherein the substituents are independently selected from the group consisting of (d_4)alkyl, (d_4)alkoxy, trifluoromethyl, and halogen; preferred from (d-4)alkyl, (d-4)alkoxy and halogen. In a preferred sub-embodiment, 2,3-dihydro- benzofuranyl-, benzo[1 ,3]dioxolyl-, 2,3-dihydro-benzo[1 ,4]dioxinyl-, AH- benzo[1 ,3]dioxinyl-, 2/-/-chromenyl-, chromanyl-, and 3-biphenyl groups are preferably unsubstituted. 3,4-Dihydro-2H-benzo[1 ,4]oxazinyl groups are preferably unsubstituted or mono-substituted with (d-4)alkyl (especially methyl). In another preferred sub- embodiment, a 2,3-dihydro-benzofuranyl group may also be disubstituted, wherein the substituents are independently selected from halogen and (d-4)alkoxy.
Examples of R1 representing "aryl" are naphthyl, 3-bromophenyl, 3-nitrophenyl, 3- biphenyl, 2,3-dihydro-benzofuran-4-yl, 2,3-dihydro-benzofuran-7-yl, 7-chloro-2- methoxy-2,3-dihydro-benzofuran-4-yl, 4H-benzo[1 ,3]dioxin-5-yl, 4H-benzo[1 ,3]dioxin-8- yl, benzo[1 ,3]dioxol-4-yl, 2,3-dihydro-benzo[1 ,4]dioxin-5-yl, chromen-5-yl, chroman-5- yl, chroman-8-yl, 3,4-dihydro-2/-/-benzo[1 ,4]oxazin-5-yl, 4-methyl-3,4-dihydro-2H- benzo[1 ,4]oxazine-5-yl, 3,4-dihydro-2/-/-benzo[1 ,4]oxazin-8-yl, and 4-methyl-3,4- dihydro-2H-benzo[1 ,4]oxazine-8-yl. Preferred are 2,3-dihydro-benzofuran-4-yl, 2,3- dihydro-benzofuran-7-yl, 7-chloro-2-methoxy-2,3-dihydro-benzofuran-4-yl, 2,3-dihydro- benzo[1 ,4]dioxin-5-yl, chroman-5-yl, chroman-8-yl, 3,4-dihydro-2/-/-benzo[1 ,4]oxazin-5- yl, 4-methyl-3,4-dihydro-2H-benzo[1 ,4]oxazine-5-yl, 3,4-dihydro-2/-/-benzo[1 ,4]oxazin- 8-yl, and 4-methyl-3,4-dihydro-2H-benzo[1 ,4]oxazine-8-yl. In another embodiment, preferred examples of R1 representing "aryl" are 2,3-dihydro-benzo[1 ,4]dioxinyl and 3-bromophenyl.
The term "heteroaryl" means a 5- to 10-membered monocyclic or bicyclic (preferred 8- to 9-membered bicyclic) aromatic ring containing 1 , 2 or 3 heteroatoms, each independently selected from oxygen, nitrogen and sulfur. Examples of such heteroaryl groups are furanyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, thiazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, pyridyl, pyrimidyl, pyridazinyl, pyrazinyl, indolyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, indazolyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzotriazolyl, benzoxadiazolyl, benzothiadiazolyl, quinolinyl, isoquinolinyl, naphthyridinyl, cinnolinyl, quinazolinyl, quinoxalinyl, phthalazinyl, pyrazolo[1 ,5-a]pyridyl, pyrazolo[1 ,5-a]pyrimidyl, imidazo[1 ,2-a]pyridyl and imidazo[2,1 -b]thiazolyl. In addition to the above list, further examples are benzoisothiazolyl, and pyrrolo[2,1 -b]thiazolyl. Preferred examples are thienyl, thiazolyl, pyrazolyl, pyridyl, indolyl, benzofuranyl, indazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoxadiazolyl, benzothiadiazolyl, imidazo[1 ,2- a]pyridyl, imidazo[2,1 -b]thiazolyl, benzoisothiazolyl, and pyrrolo[2,1 -b]thiazolyl. In another embodiment, preferred examples are benzisoxazolyl, benzoxadiazolyl, benzothiadiazolyl, imidazo[1 ,2-a]pyridyl, imidazo[2,1 -b]thiazolyl, benzoisothiazolyl, and pyrrolo[2,1 -b]thiazolyl. The above-mentioned heteroaryl groups are unsubstituted, mono-, di-, or tri-substituted (preferred unsubstituted, mono-, or di-substituted) wherein the substituents are independently selected from the group consisting of (d-4)alkyl, (d- 4)alkoxy, halogen, hydroxy-(d-4)alkyl, and trifluoromethyl; especially from (d-4)alkyl, (Ci-4)alkoxy, halogen, and trifluoromethyl; preferred from (Ci-4)alkyl, halogen, and trifluoromethyl. In another embodiment, preferred examples of such heteroaryl groups are thienyl, pyridyl, indolyl, indazolyl, benzofuranyl, and imidazo[2,1 -b]thiazolyl, which groups may be unsubstituted, mono-, di-, or tri-substituted (preferred unsubstituted, mono-, or di-substituted, most preferred unsubstituted, or mono-substituted) wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (d- 4)alkoxy, halogen, and trifluoromethyl (preferred (C1-4)alkyl, and halogen).
In particular, the above mentioned "heteroaryl" groups as used for the substituent "R1" are preferably substituted as follows: thienyl groups are substituted with halogen; thiazolyl groups are di-substituted with (C1 -4)alkyl; pyrazolyl groups are di-substituted with (C1-4)alkyl; pyridyl groups are mono-substituted with halogen; indolyl groups are mono-substituted with (Ci-4)alkyl (especially methyl); indazolyl groups are unsubstituted or mono-substituted with (Ci-4)alkyl (especially methyl); benzoxazolyl groups are unsubstituted, or mono-substituted with (Ci-4)alkyl (especially methyl); benzothiazolyl groups are unsubstituted or mono-substituted with halogen; benzisoxazolyl, benzoxadiazolyl, benzothiadiazolyl, and benzoisothiazolyl groups are unsubstituted; imidazo[1 ,2-a]pyridyl are unsubstituted or mono-substituted with (Ci-4)alkyl (especially methyl); pyrrolo[2,1 -b]thiazolyl groups are unsubstituted or mono-substituted with (d- 4)alkyl (especially methyl); and imidazo[2,1 -b] thiazolyl groups are mono-substituted with (Ci-4)alkyl (especially methyl); benzofuranyl groups are preferably unsubstituted, mono-, or di-substituted wherein the substituents are independently selected from (d- 4)alkyl, halogen, hydroxy-(d-4)alkyl, and trifluoromethyl, especially from (d-4)alkyl, halogen, and trifluoromethyl. Examples of said benzofuranyl groups are benzofuran-4- yl, 7-chloro-benzofuran-4-yl, 7-fluoro-benzofuran-4-yl, 2-fluoro-benzofuran-4-yl, 3- methyl-benzofuran-4-yl, 2-methyl-benzofuran-4-yl, 2-hydroxymethyl-benzofuran-4-yl, 5- chloro-2-methyl-benzofuran-4-yl, 7-chloro-2-methyl-benzofuran-4-yl, 7-fluoro-2-methyl- benzofuran-4-yl, 6-chloro-2-methyl-benzofuran-4-yl, 6-fluoro-2-methyl-benzofuran-4-yl, 2,3-dimethyl-benzofuran-4-yl, 2-trifluoromethyl-benzofuran-4-yl, 7-trifluoromethyl- benzofuran-4-yl, 2-methyl-6-trifluoromethyl-benzofuran-4-yl, and 2-methyl-7- trifluoromethyl-benzofuran-4-yl. ii) A further embodiment of the invention relates to thiazolidine derivatives of formula (I) according to embodiment i), wherein the stereogenic center at the thiazolidine ring is in (R)-configuration. iii) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) or ii), wherein A represents
Figure imgf000007_0001
iv) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to iii), wherein A represents
Figure imgf000007_0002
v) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to iv), wherein X represents S. vi) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to iv), wherein X represents O. vii) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to vi), wherein R2 represents methyl. viii) A further embodiment of the invention relates to thiazolidine derivatives according to embodiments i) or ii), wherein A represents
Figure imgf000007_0003
ix) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to viii), wherein D represents unsubstituted, mono-, di-, or tri-substituted phenyl, wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (Ci-4)alkoxy, trifluoromethyl, and halogen. x) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to ix), wherein
R1 represents aryl, wherein the aryl group is selected from the group consisting of a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, a 4/-/-benzo[1 ,3]dioxinyl, a 2/-/-chromenyl-, a chromanyl-, and a 3,4-dihydro-2H- benzo[1 ,4]oxazinyl group, wherein said groups are unsubstituted, mono-, or di- substituted wherein the substituents are independently selected from the group consisting of (d-4)alkyl, (d-4)alkoxy and halogen; or R1 represents heteroaryl, which is unsubstituted, mono-, di, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci- 4)alkyl, (d.4)alkoxy, halogen, hydroxy-(Ci_4)alkyl, and trifluoromethyl. xi) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to x), wherein R1 represents heteroaryl, wherein said hetereroaryl is selected from the group consisting of thienyl, thiazolyl, pyrazolyl, pyridyl, indolyl, benzofuranyl, indazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoxadiazolyl, benzothiadiazolyl, imidazo[1 ,2-a]pyridyl, imidazo[2,1 -b]thiazolyl, benzoisothiazolyl, and pyrrolo[2,1 -b]thiazolyl, wherein said groups are unsubstituted, mono-, di-, or tri-substituted (preferred unsubstituted, mono-, or di-substituted), wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci- 4)alkoxy, halogen, hydroxy-(Ci-4)alkyl, and trifluoromethyl. xii) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to x), wherein R1 represents heteroaryl, wherein said hetereroaryl is selected from the group consisting of benzisoxazolyl, benzoxadiazolyl, benzothiadiazolyl, imidazo[1 ,2-a]pyridyl, imidazo[2,1 -b]thiazolyl, benzoisothiazolyl, and pyrrolo[2,1 -b]thiazolyl, wherein said groups are unsubstituted, mono-, or di-substituted wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, and trifluoromethyl. xiii) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to xi), wherein, in case R1 represents heteroaryl, it represents a group selected from
Figure imgf000009_0001
and benzofuranyl which is unsubstituted, mono, or di-substituted wherein the substituents are independently selected from (Ci-4)alkyl, halogen, hydroxy-(d-4)alkyl, and trifluoromethyl. xiv) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to xi), wherein R1 represents heteroaryl, wherein said hetereroaryl is selected from the group consisting of thienyl, pyridyl, indolyl, benzofuranyl, indazolyl, and imidazo[2,1 -b]thiazolyl, wherein said groups are unsubstituted, mono-, di-, or tri-substituted wherein the substituents are independently selected from the group consisting of (d-4)alkyl, (d-4)alkoxy, halogen, and trifluoromethyl. xv) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to ix), wherein R1 represents a naphthyl- or a phenyl group (preferred) which is unsubstituted, mono-, di-, or tri-substituted (preferred: mono- substituted), wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci_4)alkoxy, trifluoromethyl, halogen and nitro (especially from (Ci-4)alkyl, (Ci-4)alkoxy, halogen, and trifluoromethyl (preferred: halogen)). xvi) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to x), wherein
R1 represents aryl, wherein the aryl group is selected from the group consisting of a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, a 4/-/-benzo[1 ,3]dioxinyl, a 2/-/-chromenyl-, a chromanyl-, and a 3,4-dihydro-2H- benzo[1 ,4]oxazinyl group, wherein said groups are unsubstituted, mono-, or di- substituted wherein the substituents are independently selected from the group consisting of (d-4)alkyl, (d-4)alkoxy and halogen. xvii) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to x) or xvi), wherein, in case R1 represents an aryl group, said aryl group is selected from the group consisting of a 2,3-dihydro-benzofuranyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, a chromanyl-, and a 3,4-dihydro-2H-benzo[1 ,4]oxazinyl group, wherein said groups are unsubstituted, mono-, or di-substituted wherein the substituents are independently selected from the group consisting of (d-4)alkyl, (Ci_ 4)alkoxy and halogen. xviii) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to x), or xvi), wherein, in case R1 represents an aryl group, said aryl group is selected from the group consisting of a 2,3-dihydro- benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, or a AH- benzo[1 ,3]dioxinyl group, wherein said groups are unsubstituted. xix) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to xi), wherein R1 represents a group selected from
Figure imgf000010_0001
xx) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to xi), wherein R1 represents a group selected from
Figure imgf000010_0002
xxi) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to xi), wherein R1 represents a group selected from
Figure imgf000011_0001
xxii) A further embodiment of the invention relates to thiazolidine derivatives according to any one of embodiments i) to xi) or xxi), wherein R1 represents
Figure imgf000011_0002
xxiii) A further embodiment of the invention relates to thiazolidine derivatives of formula (I) according to embodiments i) or ii) wherein A represents
Figure imgf000011_0003
X represents S, or O; D represents unsubstituted, mono-, or di-substituted phenyl, wherein the substituents are independently selected from the group consisting of (C1 -4)alkyl, (Ci-4)alkoxy, trifluoromethyl, and halogen; and
R1 represents a group selected from 2,3-dihydro-benzofuran-4-yl, 2,3-dihydro- benzofuran-7-yl, 7-chloro-2-methoxy-2,3-dihydro-benzofuran-4-yl, 2,3-dihydro- benzo[1 ,4]dioxin-5-yl, chroman-5-yl, chroman-8-yl, 3,4-dihydro-2/-/-benzo[1 ,4]oxazin-5- yl, 4-methyl-3,4-dihydro-2H-benzo[1 ,4]oxazine-5-yl, 3,4-dihydro-2H-benzo[1 ,4]oxazin- 8-yl, and 4-methyl-3,4-dihydro-2H-benzo[1 ,4]oxazine-8-yl; or R1 represents a group selected from
Figure imgf000012_0001
and benzofuranyl which is unsubstituted, mono, or di-substituted wherein the substituents are independently selected from (Ci-4)alkyl, halogen, hydroxy-(d-4)alkyl, and trifluoromethyl; or R1 represents phenyl which is mono-substituted with halogen or nitro, naphthyl, pyridyl which is mono-substituted with halogen, thienyl which is mono-substituted with halogen, thiazolyl which is disubstituted with (C1-4)alkyl, or pyrazolyl which is disubstituted with (d-4)alkyl (especially R1 represents
Figure imgf000012_0002
phenyl which is mono-substituted with halogen, pyridyl which is mono-substituted with halogen, or thienyl which is mono-substituted with halogen).
The compounds of formula (I) may contain one or more stereogenic or asymmetric centers, such as one or more asymmetric carbon atoms. Substituents at a double bond may be present in the Z- or E-configuration unless indicated otherwise. The compounds of formula (I) may thus be present as mixtures of stereoisomers or preferably as pure stereoisomers. Mixtures of stereoisomers may be separated in a manner known to a person skilled in the art.
Where the plural form is used for compounds, salts, pharmaceutical compositions, diseases and the like, this is intended to mean also a single compound, salt, or the like. Any reference to a compound of formula (I) is to be understood as referring also to the salts (and especially the pharmaceutically acceptable salts) of such compounds, as appropriate and expedient.
The term "pharmaceutically acceptable salts" refers to non-toxic, inorganic or organic acid and/or base addition salts. Reference can be made to "Salt selection for basic drugs", Int. J. Pharm. (1986), 33, 201 -217.
Examples of preferred compounds of formula (I) according to embodiment i) are selected from the group consisting of:
Benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(2-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(3-methoxy-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; Benzofuran-4-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(3,4-difluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(2-methoxy-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl-phenyl)-oxazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-oxazole-4-carbonyl)-thiazolidin-
4-ylmethyl]-amide; Benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-oxazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid [(R)-3-(2-methyl-4-p-tolyl-thiazole-5-carbonyl)-thiazolidin-
4-ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-oxazole-4-carbonyl)-thiazolidin- 4-ylmethyl]-amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(3,4-dichloro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; Benzofuran-4-carboxylic acid {(R)-3-[5-(4-methoxy-phenyl)-2-methyl-oxazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid [(R)-3-(4'-methyl-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide; Benzofuran-4-carboxylic acid [(R)-3-(3',4'-dimethyl-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(3'-methyl-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(3'-methoxy-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(4'-fluoro-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(4'-methoxy-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide; 2,3-Dihydro-benzo[1 ,4]dioxine-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-phenyl-thiazole-4-carbonyl)-thiazolidin- 4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-5-phenyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[2-methyl-5-(4-trifluoromethyl-phenyl)- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(3,4-dimethyl-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(2-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(3-methoxy-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl-phenyl)- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(3,4-difluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; Benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)-thiazolidin-
4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(2-methoxy-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl-phenyl)- oxazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-oxazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-oxazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-4-p-tolyl-thiazole-5-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-oxazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(3,4-dichloro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(4-methoxy-phenyl)-2-methyl-oxazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(4'-methyl-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(3',4'-dimethyl-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
Benzofuran-4-carboxylic acid {(R)-3-[2-methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(3'-methyl-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(3'-methoxy-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(4'-fluoro-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(4'-methoxy-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
3-Bromo-N-{(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-thiazolidin-4- ylmethylj-benzamide; 1 -Methyl-1 H-indole-2-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
4-Bromo-thiophene-2-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Bromo-pyridine-2-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
2,3-Dihydro-benzo[1 ,4]dioxine-5-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)-thiazolidin-4-ylmethyl]- amide; Benzofuran-4-carboxylic acid {(R)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
N-[(R)-3-(Biphenyl-2-carbonyl)-thiazolidin-4-ylmethyl]-3-bromo-benzamide;
1 -Methyl-1 H-indole-2-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
4-Bromo-thiophene-2-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
6-Bromo-pyridine-2-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)-thiazolidin-4-ylmethyl]- amide; and
Benzofuran-4-carboxylic acid {(R)-3-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide.
Further examples of preferred compounds of formula (I) according to embodiment i) are selected from the group consisting of: Naphthalene-1 -carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
5-tert-Butyl-2-methyl-2/-/-pyrazole-3-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 2,3-Dihydro-benzofuran-7-carboxylic acid {(R)-3[5-(4-fluoro-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2,4-Dimethyl-thiazole-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; Λ/-{(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-3- nitro-benzamide;
Benzo[£>]thiophene-2-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
2-Methyl-benzooxazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; lmidazo[1 ,2-a]pyridine-3-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide; 2-Methyl-imidazo[1 ,2-a]pyridine-3-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2,3-Dimethyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
3,4-Dihydro-2H-benzo[1 ,4]oxazine-5-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole- 4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
4-Methyl-3,4-Dihydro-2/-/-benzo[1 ,4]oxazine-5-carboxylic acid [(R)-3-(2-methyl-5-m- tolyl-thiazole-4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
Chroman-5-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-thiazolidin-4- ylmethyl]-amide; Chroman-8-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-thiazolidin-4- ylmethyl]-amide;
3,4-Dihydro-2H-benzo[1 ,4]oxazine-8-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-
4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
4-Methyl-3,4-Dihydro-2/-/-benzo[1 ,4]oxazine-8-carboxylic acid [(R)-3-(2-methyl-5-m- tolyl-thiazole-4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
BenzoIcdisoxazole-S-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
BenzoIcdisothiazole-S-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide; 1 -Methyl-1 /-/-indazole-3-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
2,3-Dihydro-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; 2,3-Dihydro-benzo[1 ,4]dioxine-5-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2-Methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; lmidazo[1 ,2-a]pyridine-3-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Methyl-imidazo[1 ,2-a]pyridine-3-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2,3-Dimethyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 3,4-Dihydro-2/-/-benzo[1 ,4]oxazine-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
4-Methyl-3,4-dihydro-2/-/-benzo[1 ,4]oxazine-5-carboxylic acid {(R)-3-[5-(4-fluoro- phenyl)-2-methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
Chroman-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
Chroman-8-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
3,4-Dihydro-2H-benzo[1 ,4]oxazine-8-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 4-Methyl-3,4-dihydro-2/-/-benzo[1 ,4]oxazine-8-carboxylic acid {(R)-3-[5-(4-fluoro- phenyl)-2-methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2,3-Dihydro-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzooxazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
Benzooxazole-7-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Methyl-benzooxazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; 2-Methyl-benzooxazole-7-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzothiazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide; Benzothiazole-7-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
7-Chloro-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
7-Chloro-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
7-Fluoro-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
7-Fluoro-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; Pyrrolo[2,1 -/?]thiazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
Pyrrolo[2,1 -/?]thiazole-7-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-pyrrolo[2,1 -/?]thiazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Methyl-pyrrolo[2,1 -/?]thiazole-7-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
7-Chloro-2-methoxy-2,3-dihydro-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m- tolyl-thiazole-4-carbonyl)-thiazolidin-4-ylmethyl]-amide; 7-Chloro-2-methoxy-2,3-dihydro-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro- phenyl)-2-methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Chloro-benzothiazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2-Chloro-benzothiazole-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole- 4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzothiazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
Benzothiazole-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; Benzo[2,1 ,3]thiadiazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
Benzo[2,1 ,3]thiadiazole-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 7-Trifluoromethyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
7-Trifluoromethyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
3-Methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
3-Methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzo[2,1 ,3]oxadiazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; Benzo[2,1 ,3]oxadiazole-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Hydroxymethyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2-Hydroxymethyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
5-Chloro-2-methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 7-Chloro-2-methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
7-Fluoro-2-methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2-Methyl-7-trifluoromethyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl- thiazole-4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Chloro-2-methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Fluoro-2-methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; 2-Methyl-6-trifluoromethyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl- thiazole-4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
5-Chloro-2-methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; 7-Chloro-2-methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
7-Fluoro-2-methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Methyl-7-trifluoromethyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Chloro-2-methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Fluoro-2-methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 2-Methyl-6-trifluoromethyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; and
2-Trifluoromethyl-benzofuran-4-carboxylic acid [3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide.
Further examples of preferred compounds of formula (I) according to embodiment i) are selected from the group consisting of:
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; θ-Methyl-imidazo^J -blthiazole-δ-carboxylic acid [(R)-3-(2-methyl-5-phenyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; θ-Methyl-imidazo^J -blthiazole-δ-carboxylic acid {(R)-3-[2-methyl-5-(4-trifluoromethyl- phenyl)-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(3-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(3,4-dimethyl-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(2-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(3-methoxy-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; θ-Methyl-imidazo^J -blthiazole-S-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl- phenyl)-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(3,4-difluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -/?]thiazole-5-carboxylic acid {(R)-3-[5-(2-methoxy-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; θ-Methyl-imidazo^J -bJthiazole-S-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl- phenyl)-oxazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; θ-Methyl-imidazo^J -blthiazole-S-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-oxazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- oxazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(2-methyl-4-p-tolyl-thiazole-5- carbonyl)-thiazolidin-4-ylmethyl]-amide; θ-Methyl-imidazo^J -blthiazole-S-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-oxazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(3,4-dichloro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(4-methoxy-phenyl)-2- methyl-oxazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; θ-Methyl-imidazo^J -blthiazole-S-carboxylic acid [(R)-3-(4'-methyl-biphenyl-2- carbonyl)-thiazolidin-4-ylmethyl]-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(3',4'-dimethyl-biphenyl-2- carbonyl)-thiazolidin-4-ylmethyl]-amide; θ-Methyl-imidazo^J -blthiazole-S-carboxylic acid [(R)-3-(3'-methyl-biphenyl-2- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(3'-methoxy-biphenyl-2- carbonyl)-thiazolidin-4-ylmethyl]-amide; θ-Methyl-imidazo^J -blthiazole-S-carboxylic acid [(R)-3-(4'-fluoro-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide; θ-Methyl-imidazo^J -bJthiazole-S-carboxylic acid [(R)-3-(4'-methoxy-biphenyl-2- carbonyl)-thiazolidin-4-ylmethyl]-amide; and 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide.
The compounds of formula (I) and their pharmaceutically acceptable salts can be used as medicaments, e.g. in the form of pharmaceutical compositions for enteral or parenteral administration.
The production of the pharmaceutical compositions can be effected in a manner which will be familiar to any person skilled in the art (see for example Remington, The Science and Practice of Pharmacy, 21 st Edition (2005), Part 5, "Pharmaceutical Manufacturing" [published by Lippincott Williams & Wilkins]) by bringing the described compounds of formula (I) or their pharmaceutically acceptable salts, optionally in combination with other therapeutically valuable substances, into a galenical administration form together with suitable, non-toxic, inert, therapeutically compatible solid or liquid carrier materials and, if desired, usual pharmaceutical adjuvants.
The present invention also relates to a method for the prevention or treatment of a disease or disorder mentioned herein comprising administering to a subject a pharmaceutically active amount of a compound of formula (I).
The compounds according to formula (I) may be used for the preparation of a medicament and are suitable for the prevention or treatment of diseases selected from the group consisting of dysthymic disorders including major depression and cyclothymia, affective neurosis, all types of manic depressive disorders, delirium, psychotic disorders, schizophrenia, catatonic schizophrenia, delusional paranoia, adjustment disorders and all clusters of personality disorders; schizoaffective disorders; anxiety disorders including generalized anxiety, obsessive compulsive disorder, posttraumatic stress disorder, panic attacks, all types of phobic anxiety and avoidance; separation anxiety; all psychoactive substance use, abuse, seeking and reinstatement; all types of psychological or physical addictions, dissociative disorders including multiple personality syndromes and psychogenic amnesias; sexual and reproductive dysfunction; psychosexual dysfunction and addiction; tolerance to narcotics or withdrawal from narcotics; increased anaesthetic risk, anaesthetic responsiveness; hypothalamic-adrenal dysfunctions; disturbed biological and circadian rhythms; sleep disturbances associated with diseases such as neurological disorders including neuropathic pain and restless leg syndrome; sleep apnea; narcolepsy; chronic fatigue syndrome; insomnias related to psychiatric disorders; all types of idiopathic insomnias and parasomnias; sleep-wake schedule disorders including jet-lag; all dementias and cognitive dysfunctions in the healthy population and in psychiatric and neurological disorders; mental dysfunctions of aging; all types of amnesia; severe mental retardation; dyskinesias and muscular diseases; muscle spasticity, tremors, movement disorders; spontaneous and medication-induced dyskinesias; neurodegenerative disorders including Huntington's, Creutzfeld-Jacob's, Alzheimer's diseases and Tourette syndrome; Amyotrophic lateral sclerosis; Parkinson's disease; Cushing's syndrome; traumatic lesions; spinal cord trauma; head trauma; perinatal hypoxia; hearing loss; tinnitus; demyelinating diseases; spinal and cranial nerve diseases; ocular damage; retinopathy; epilepsy; seizure disorders; absence seizures, complex partial and generalized seizures; Lennox-Gastaut syndrome; migraine and headache; pain disorders; anaesthesia and analgesia; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; dental pain; pain related to infection e.g. by HIV; post- chemotherapy pain; post-stroke pain; post-operative pain; neuralgia; osteoarthritis; conditions associated with visceral pain such as irritable bowel syndrome; eating disorders; diabetes; toxic and dysmetabolic disorders including cerebral anoxia, diabetic neuropathies and alcoholism; appetite, taste, eating, or drinking disorders; somatoform disorders including hypochondriasis; vomiting/nausea; emesis; gastric dyskinesia; gastric ulcers; Kallman's syndrome (anosmia); impaired glucose tolerance; intestinal motility dyskinesias; hypothalamic diseases; hypophysis diseases; hyperthermia syndromes, pyrexia, febrile seizures, idiopathic growth deficiency; dwarfism; gigantism; acromegaly; basophil adenoma; prolactinoma; hyperprolactinemia; brain tumors, adenomas; benign prostatic hypertrophy, prostate cancer; endometrial, breast, colon cancer; all types of testicular dysfunctions, fertility control; reproductive hormone abnormalities; hot flashes; hypothalamic hypogonadism, functional or psychogenic amenorrhea; urinary bladder incontinence; asthma; allergies; all types of dermatitis, acne and cysts, sebaceous gland dysfunctions; cardiovascular disorders; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; dyslipidemias, hyperlipidemias, insulin resistance; urinary retention; osteoporosis; angina pectoris; myocardial infarction; arrhythmias, coronary diseases, left ventricular hypertrophy; ischemic or haemorrhagic stroke; all types of cerebrovascular disorders including subarachnoid haemorrhage, ischemic and hemorrhagic stroke and vascular dementia; chronic renal failure and other renal diseases; gout; kidney cancer; urinary incontinence; and other diseases related to general orexin system dysfunctions.
Compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of psychoactive substance use and abuse, of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders.
Eating disorders may be defined as comprising metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa. Pathologically modified food intake may result from disturbed appetite (attraction or aversion for food); altered energy balance (intake vs. expenditure); disturbed perception of food quality (high fat or carbohydrates, high palatability); disturbed food availability (unrestricted diet or deprivation) or disrupted water balance. Drinking disorders include polydipsias in psychiatric disorders and all other types of excessive fluid intake. Sleep disorders include all types of parasomnias, insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias; restless leg syndrome; sleep apneas; jet-lag syndrome; shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders. Insomnias are defined as comprising sleep disorders associated with aging; intermittent treatment of chronic insomnia; situational transient insomnia (new environment, noise) or short-term insomnia due to stress; grief; pain or illness. Insomnia also include stress-related syndromes including post-traumatic stress disorders as well as other types and subtypes of anxiety disorders such as generalized anxiety, obsessive compulsive disorder, panic attacks and all types of phobic anxiety and avoidance; psychoactive substance use, abuse, seeking and reinstatement are defined as all types of psychological or physical addictions and their related tolerance and dependence components. Cognitive dysfunctions include deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.
In a further preferred embodiment of the invention compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of sleep disorders that comprises all types of insomnias, narcolepsy and other disorders of excessive sleepiness, sleep-related dystonias, restless leg syndrome, sleep apneas, jet-lag syndrome, shift-work syndrome, delayed or advanced sleep phase syndrome or insomnias related to psychiatric disorders.
In another preferred embodiment of the invention compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of cognitive dysfunctions that comprise deficits in all types of attention, learning and memory functions occurring transiently or chronically in the normal, healthy, young, adult or aging population, and also occurring transiently or chronically in psychiatric, neurologic, cardiovascular and immune disorders.
In another preferred embodiment of the invention compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of eating disorders that comprise metabolic dysfunction; dysregulated appetite control; compulsive obesities; emeto-bulimia or anorexia nervosa.
In another preferred embodiment of the invention compounds of formula (I) are particularly suitable for use in the treatment of diseases or disorders selected from the group consisting of psychoactive substance use and abuse that comprise all types of psychological or physical addictions and their related tolerance and dependence components.
Preparation of compounds of formula (I): A further aspect of the invention is a process for the preparation of compounds of formula (I). Compounds according to formula (I) of the present invention can be prepared according to the general sequence of reactions outlined in the schemes below wherein A, D, X, R1 and R2 are as defined for formula (I). The compounds obtained may also be converted into pharmaceutically acceptable salts thereof in a manner known per se.
In general, all chemical transformations can be performed according to well-known standard methodologies as described in the literature or as described in the procedures below.
Figure imgf000027_0001
Scheme 1 : Preparation of compounds of formula (I)
Thiazolidine derivatives of formula (I) may be prepared by reacting a thiazolidine derivative of structure (3) with an acid of the general formula A-COOH in a polar aprotic solvent such as DMF, THF, DCM at RT in the presence of a coupling reagent such as TBTU, EDC/HOAt, HATU in the presence of a base such as TEA, DIPEA, DMAP. Acids of the general formula A-COOH are commercially available or synthesized according to methods described below.
Thiazolidine derivates of structure (3) may be prepared by treatment of compounds of structure (2) with acids such as HCI in dioxane, TFA in DCM, neat TFA at RT. Compounds of structure (3) may be used as free base or salts thereof such as the hydrochloride salt.
A compound of structure (2) may be prepared by reacting 4-aminomethyl-thiazolidine- 3-carboxylic acid tert-butyl ester of structure (1 ), which is commercially available, with an acid of the general formula R1-COOH in a polar aprotic solvent such as DMF, THF, DCM at RT in the presence of a coupling reagent such as TBTU, EDC, HATU in presence or absence of additives such as HOBt, HOAt in the presence of a base such as TEA, DIPEA, DMAP. Acids of the general formula R1COOH are commercially available, or synthesized according to methods described below. Preparation of carboxylic acids A-COOH
Carboxylic acid derivatives A-COOH wherein A represents a thiazole-4-yl derivative are commercially available or can be synthesised according to scheme 2.
Figure imgf000027_0002
(5) (6) (7) (8)
Scheme 2: Synthesis of carboxylic acids A-COOH wherein A represents a thiazole-4-yl derivative By reaction of methyl dichloroacetate (5) with an aldehyde of the formula D-CHO in the presence of a base such as KOfBu in an aprotic polar solvent such as THF at RT 3-chloro-2-oxo-propιonιc acid ester derivatives (6) are obtained. Compounds of structure (6) can be transformed by reaction with commercially available thioamides R2-C(S)-NH2 at RT in solvents such as MeCN to provide thιazol-4-carboxylιc acid ester derivatives (7). Saponification of the ester function using methods known in the art such as treatment with a base such as sodium hydroxide in a solvent such as methanol provides the corresponding thιazol-4-carboxylιc acid derivatives (8). Aldehydes of formula D-CHO are commercially available or well known in the art. Carboxylic acid derivatives A-COOH wherein A represents a thιazole-5-yl derivative which are commercially available or synthesised according to scheme 3.
Figure imgf000028_0001
(9) (10) (11) (12)
Scheme 3: Synthesis of carboxylic acids A-COOH wherein A represents a thιazole-5-yl derivative By refluxing a commercially available 3-oxo-propιonιc acid ester derivative (9) with SO2CI2 in a solvent such as CHCI3 the corresponding 2-chloro-3-oxo-propιonιc acid ester derivatives (10) can be obtained. Compounds of structure (10) can be transformed by reaction with commercially available thioamides R2-C(S)-NH2 at reflux temperature in solvents such as THF in presence of a base such as NaHCO3 to the corresponding thιazol-5-carboxylιc acid ester derivatives (1 1 ). Saponification of the ester function using methods known in the art such as treatment with a base such as KOH in a solvent such as ethanol provides the corresponding thιazol-5-carboxylιc acid derivatives (12).
Carboxylic acid derivatives A-COOH wherein A represents a oxazole-4-yl derivative which are commercially available or synthesised according to scheme 4.
Figure imgf000029_0001
(16) (17)
Scheme 4: Synthesis of carboxylic acids A-COOH wherein A represents an oxazole-4- yl derivative
By reaction of a commercially available 3-oxo-propionic acid ester derivative (13) with an aqueous solution of sodium nitrite in presence of an acid such as glacial acetic acid the corresponding oxime derivative (14) can be obtained. The 2-acetamido-3-oxo- propionic acid ester derivative (15) can be synthesized from compounds of structure (14) using acetic anhydride in presence of an acid such as glacial acetic acid and catalytic amounts of metal chlorides such as mercury chloride and zinc powder. Cyclization to the corresponding corresponding oxazole-4 carboxylic acid ester derivative (16) can be achieved under dehydrating conditions such as thionyl chloride in chloroform. Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in solvent mixtures such as ethanol/water provides the corresponding oxazole-4 carboxylic acid derivative (17).
Carboxylic acid derivatives A-COOH wherein A represents a phenyl-2-yl derivative are commercially available or can be synthesised according to scheme 5.
Figure imgf000029_0002
Scheme 5: Synthesis of carboxylic acids A-COOH wherein A represents a phenyl-2-yl derivative Reaction of commercially available (2-carboxyphenyl)-boronic acid derivatives (18) or esters thereof with commercially available aryl-bromides or aryl-iodides of formula D-Br or D-I in presence of a catalyst such as Pd(PPh3)4 and a base such as Na2CO3 under heating in a solvent such as toluene, dioxane, THF provides, after saponification, if needed, of the ester using well known methods, the corresponding phenyl- 2-carboxylic acid derivatives (19). Alternatively, reaction of commercially available 2-bromo-, or 2-iodo-benzoic acid, or esters thereof, with commercially available boronic acid derivatives of formula D-B(OH)2 using the conditions described before provides the corresponding phenyl-2-carboxylic acid derivatives (19). Synthesis of Carboxylic Acids R1-COOH
Carboxylic acids of formula R1-COOH are commercially available or well known in the art (Lit. e.g. WO2001/96302; T. Eicher, S. Hauptmann "The chemistry of Heterocycles: Structure, Reactions, Syntheses, and Applications", 2nd Edition 2003, Wiley, ISBN 978-3-527-30720-3). Carboxylic acid derivatives R1-COOH which represent an imidazo[2,1 -b]thiazole- 2-carboxylic acid derivative are commercially available or can be synthesised according to scheme 6.
Pathway A: By reaction of 2-chloro-3-oxo-butyric acid methyl ester (20) with thiourea the amino-thiazole (21 ) can be obtained. Transformation to ester (22) can be accomplished with bromoacetaldehydewhich can be generated in-situ from bromoacetaldehyde diethylacetal under acidic conditions. After saponification with bases such as sodium hydroxide the desired acid (23) can be obtained.
Pathway A
Figure imgf000030_0001
Pathway B
Figure imgf000031_0001
(24) (25) (26)
Figure imgf000031_0002
(27) (28)
Scheme 6: Synthesis of carboxylic acids R1-C00H which represent an imidazo [2,1 -b]thiazole-2-carboxylic acid derivative Pathway B: By heating a compound of structure (24) with Λ/,Λ/-dimethylformamide dimethylacetal in a solvent such as toluene formamidine derivatives (25) can be obtained. They can be alkylated with ethyl bromoacetate yielding the respective thiazolium bromide (26) which can be cyclised with strong bases such as DBU to the ester (27). Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in a solvent such as ethanol/water provides the corresponding imidazo[2,1 -b]thiazole-2-carboxylic acid derivatives (28).
Carboxylic acid derivatives R1 -COOH which represent a pyrrolo[2,1 -£>]thiazole- 7-carboxylic acid derivative can be synthesised according to scheme 7
By reaction of 2-methylsulfanylthiazole (29) with trimethylsilylmethyl trifluoromethanesulfonate followed by cyclisation of the resulting thiazolinium salt by reaction with ethyl propiolate in the presence of caesium fluoride, the pyrrolo[2,1 -
£>]thiazole (30) can be obtained. Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in a solvent such as
EtOH/ water provides the corresponding pyrrolo[2,1 -£>]thiazole-7-carboxylic acid derivative (31 ) (Berry CR. et al., Organic Letters, 2007, 9, 21 , 4099-4102).
Figure imgf000032_0001
(29) (30) (31 )
Figure imgf000032_0002
(CH3)2Zn/ Pd(dppf)CI2
Figure imgf000032_0003
(32) (33)
Scheme 7: Synthesis of carboxylic acids R1-C00H which represent a pyrrolo [2,1 -b]thiazole-7-carboxylic acid derivative
Bromination of (30) by reaction with NBS followed by methylation of the resulting crude ethyl 6-bromo-pyrrolo[2,1 -/?]thiazole-7-carboxylate by reaction with dimethylzinc in the presence of a palladium catalyst such as Pd(dppf)CI2 gave the ester (32). Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in a solvent such as EtOH/ water provides the corresponding 6-methyl-pyrrolo[2,1 -/?]thiazole-7-carboxylic acid derivative (33). Carboxylic acid derivatives R1-COOH which represent a 3,4-dihydro-2H- benzo[1 ,4]oxazinyl- or 3-oxo-3,4-dihydro-2/-/-benzo[1 ,4]oxazinyl-carboxylic acid derivative can be synthesised according to the literature according to schemes 8 and 9.
Esterification of 3-hydroxy-anthranilic acid (34) with concentrated sulphuric acid in EtOH provides the corresponding ethyl ester (35). Cyclisation with acetyl chloride in presence of a base such as K2CO3 in a solvent such as DMF provides 3-oxo-3,4- dihydro-2H-benzo[1 ,4]oxazine derivatives (36). Compounds of structure (36) can optionally be alkylated with alkylating reagents such as methyl iodide in presence of a base such as K2CO3. Saponification with a base such as NaOH in a solvent such as EtOH/ water leads to the corresponding acids (37) or (38). Reduction of compounds of structure (36) with NaBH4 in the presence of BF3-diethyl etherate leads to the corresponding 3,4-dihydro-2/-/-benzo[1 ,4]oxazine derivative which can optionally be alkylated and/or saponified as described before to provide the corresponding acids (40) or (41 ) (Kuroita T. et al, Chemical Pharmaceutical Bulletin 1996,44,4,756-764).
Figure imgf000033_0001
Scheme 8: Synthesis of carboxylic acids R1 -COOH which represent a 3,4-dihydro-2H- benzo[1 ,4]oxazinyl- or 3-oxo-3,4-dihydro-2/-/-benzo[1 ,4]oxazinyl-carboxylic acid derivative
Figure imgf000033_0002
(46)
Scheme 9: Synthesis of carboxylic acids R1-COOH which represent a 3,4-dihydro-2H-benzo[1 ,4] oxazinyl-carboxylic acid derivative Hydrogenation of methyl 3-nitrosalicylate (42) in presence of a palladium catalyst provides the aniline derivative (43) which can be cyclized with chloroacetyl chloride as described before to the ester (44). Reduction of compounds of structure (44) with NaBH4 in the presence of BF3-diethyl etherate leads to the corresponding 3,4-dihydro- 2H-benzo[1 ,4]oxazine derivative which can optionally be alkylated and/or saponified as described before to provide the corresponding acids (45) or (46) (Kuroita T. et al, Chemical Pharmaceutical Bulletin 1996, 44, 4, 756-764).
Carboxylic acid derivatives R1-COOH which represent a benzooxazole-4-carboxylic acid derivative can be synthesised according to the literature according to schemes 10 and 1 1 .
Figure imgf000034_0001
(47) (48) (49)
Scheme 10: Synthesis of carboxylic acids R1-COOH which represent a benzooxazole-4-carboxylic acid derivative
By cyclisation of ethyl 2-amino-3-hydroxybenzoate (47) with acetyl chloride in the presence of PPTS and TEA, the ester (48) can be obtained (Goldstein S.W. et al, Journal of Heterocyclic Chemistry, 1990, 27, 335-336). Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in a solvent such as EtOH / water provides the corresponding 2-methyl-benzooxazole- 4-carboxylic acid derivative (49).
Figure imgf000034_0002
(52) (50) (51 )
Scheme 1 1 : Synthesis of carboxylic acids R1-COOH which represent a benzooxazole- 7-carboxylic acid derivative
By cyclisation of 3-aminosalicylic acid (50) with triethyl orthoformate in the presence of
PTSA, the benzooxazole-7-carboxylic acid (51 ) can be obtained (WO2006/069155). By cyclisation of 3-aminosalicylic acid (50) with triethyl orthoacetate in the presence of PTSA, the 2-methyl-benzooxazole-7-carboxylic acid (52) can be obtained (WO2006/069155)
Carboxylic acid derivatives R1-COOH which represent a benzothiazole-7-carboxylic acid derivative can be synthesised according to the literature according to scheme"! 2.
Figure imgf000035_0001
(57)
Scheme 12: Synthesis of carboxylic acids R1-C00H which represent a benzothiazole- 7-carboxylic acid derivative
By reaction of methyl 3-aminobenzoate (53) with potassium thiocyanate in the presence of sulfuric acid and crown-ether 18-C-6, the thiourea (54) can be obtained. Cyclisation by reaction with bromine in acetic acid provides the 2-amino-benzothiazole derivative (55). Cleavage of the amino group by reaction with isoamyl nitrite furnishes the ester (56) (WO2005/092890). Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in a solvent such as MeOH/ water provides the corresponding benzothiazole-7-carboxylic acid derivative (57).
Carboxylic acid derivatives R1-COOH which represent a benzofuran-4-carboxylic acid derivative can be synthesised according to the literature according to schemes 13 and 14.
By reaction of methyl 3-hydroxybenzoate (58) with 3-chloro-2-butanone, the ester (59) can be obtained. Cyclisation with sulfuric acid provides the 2,3-dimethyl-benzofurane derivative (60) (Kawase Y. et al, Bulletin of the Chemical Sociaty of Japan, 1967, 40, 5, 1224-1231 ). Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in a solvent such as MeOH/ water provides the corresponding 2,3-dimethyl-benzofuran-4-carboxylic acid derivative (61 ). On the other hand, reaction of methyl 3-hydroxybenzoate (58) with crotyl bromide furnishes the ester (62) which after reaction in N,N-dimethylaniline provides the ester (63). Ozonolysis followed by reaction with PTSA gives the 3-methyl-benzofurane derivative (64) (Mohamadi F. et al, Journal of Medicinal Chemistry, 1994, 37, 232-239 and EP58906). Saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in a solvent such as MeOH/ water provides the corresponding 3-methylbenzofuran-4-carboxylic acid derivative (65).
Figure imgf000036_0001
Scheme 13: Synthesis of carboxylic acids R1-COOH which represent a 2,3-dimethyl- benzofuran-4-carboxylic acid derivative
Figure imgf000036_0002
Scheme 14: Synthesis of carboxylic acids R1-COOH which represent a 2-methylbenzofuran-4-carboxylic acid derivative
By cyclisation of 2-allyl-3-hydroxybenzaldehyde (66) with a palladium catalyst such as bis(acetonitrile)dichloropalladium in the presence of 1 ,4-benzoquinone and lithium chloride, the 2-methyl-benzofurane carbaldehyde (67) can be obtained (Danheiser R. L. et al, Organic Letters, 2005, 7, 18, 3905-3908). Oxidation of the aldehyde function with sodium chlorite in the presence of a scavenger such as 2-methyl-2-butene furnishes the corresponding 2-methylbenzofuran-4-carboxylic acid (68). Carboxylic acid derivatives R1-COOH which represent a benzofuran-4-carboxylic acid derivative and R represent Cl, F or CF3 can be synthesised according to the literature according to scheme 15.
Figure imgf000037_0001
(73) Scheme 15: Synthesis of carboxylic acids R1 -COOH which represent a substituted- benzofuran-4-carboxylic acid derivative
By esterification of phenol derivative (69) with EtOH in the presence of an acid such as sulfuric acid followed by alkylation by reaction with allyl bromide in the presence of a K2CO3 and Kl, the alkyl-ether derivative (70) can be obtained. Claisen rearrangement by reaction with N,N-dimethylaniline furnishes the phenol derivative (71 ). Ozonolysis followed by reaction with PTSA provides the benzofurane derivative (72). On the other hand ozonolysis of (71 ) in the presence of MeOH furnishes the dihydro-benzofurane derivative (74). Saponification of the ester function of (72) and (74) using methods known in the art such as treatment with a base such as NaOH in a solvent such as EtOH/ water provide the corresponding benzofuran-4-carboxylic acid derivatives (73) and (75). Furthermore, cyclisation of (71 ) with a palladium catalyst such as bis(acetonitrile)dichloropalladium in the presence of 1 ,4-benzoquinone and lithium chloride, the 2-methylbenzofurane derivative (76) can be obtained (Danheiser R. L. et al, Organic Letters, 2005, 7, 18, 3905-3908). Saponification of the ester function of (76) using methods known in the art such as treatment with a base such as NaOH in a solvent such as EtOH/ water provide the corresponding 2-methyl-benzofuran-4- carboxylic acid derivatives (77).
Carboxylic acid derivatives R1-COOH which represent a benzofuran-4-carboxylic acid derivative can be synthesised according to the literature according to scheme 16.
Figure imgf000038_0001
(80) (81 )
Scheme 16: Synthesis of carboxylic acids R1-COOH which represent a 2- hydroxymethylbenzofuran-4-carboxylic acid derivative
By alkylation of methyl 2-hydroxybenzoate (58) with allyl bromide in the presence of K2CO3 and Kl followed by Claisen rearrangement by reaction with N,N-dimethylaniline the phenol derivative (78) can be obtained. Cyclisation by reaction with mCPBA in presence of a base such as NaHCO3 furnishes the desired dihydro-benzofurane derivative (79). Acetylation by reaction with acetic anhydride followed by oxidation with DDQ provides the corresponding benzofurane derivative (80). Cleavage of the acetyl group by reaction with K2CO3 followed by saponification of the ester function using methods known in the art such as treatment with a base such as NaOH in a solvent such as MeOH/ water provide the corresponding 2-hydroxymethylbenzofuran-4- carboxylic acid derivatives (81 ).
Carboxylic acid derivatives R1-COOH which represent a 2-fluorobenzofuran-4- carboxylic acid derivative can be synthesised according to the literature according to scheme 17.
Specific electrophilic fluorination of benzofuran-4-carboxylic acid (82) (Eissenstat M.A. et al, Journal of Medicinal Chemistry 1995, 38, 16, 3094-3105) by reaction with tert- butyl lithium followed by reaction with NFSI (Torrado A. et al Bioorganic Medicinal Chemistry 2004, 12, 5277-5295 and Differling E. et al Synlett, 1991 , 1 , 187-189) provides the desired 2-fluorobenzofuran-4-carboxylic acid (83).
Figure imgf000039_0001
(82) (83)
Scheme 17: Synthesis of carboxylic acids R1-COOH which represent a 2- fluorobenzofuran-4-carboxylic acid derivative
Compounds which contain a 2-trifluoromethylbenzofurane moiety can be synthesised according to the literature according to scheme 18.
Figure imgf000039_0002
I ) CF3CO2Et
2) TFA
3) A-CO2H/ TBTU/ DIPEA , 4) sat. K2CO3
Figure imgf000039_0003
TBTU/ DIPEA
Figure imgf000039_0004
(82) (84) (87)
Figure imgf000039_0005
(88)
Scheme 18: Synthesis of compounds containing a 2-trifluoromethyl-benzofurane moiety
Specific electrophilic iodination of benzofuran-4-carboxylic acid (82) by reaction with tert-butyl lithium followed by reaction with iodine provides the desired 2-iodo- benzofuran-4-carboxylic acid (84). Amide coupling using classical methodology (i.e. TBTU/ DIPEA) with n-acyl-thiazolidine (86) derivative furnishes bis-N-acyl-thiazolidine intermediate (87). The N-acyl-thiazolidine derivatives (86) can be prepared by trifluoroacetylation of commercially available (R)-4-Aminomethyl-thiazolidine-3- carboxylic acid tert-butyl ester (85) with ethyl trifluoroacetate followed by removal of the Boc-protecting group with TFA, acylation with A-CO2H using classical amide coupling methodology (TBTU/ DIPEA) and finally removal of the trifluoroacetyl-protecting group by reaction with sat. K2CO3. Trifluoromethylation of (87) with methyl (fluorosulfonyl)difluoroacetate in the presence of copper (I) iodide in a mixture of HMPA/ DMF (Chen Q. et al Journal of Chemical Society: Chemical Communications 1989, 1 1 , 705-706 and Chen Q. et al Journal of Fluorine Chemistry. 1991 , 55, 3, 291 - 298) provides the 2-trifluoromethyl-benzofurane thiazolidine derivatives (88).
Whenever the compounds of formula (I) are obtained in the form of mixtures of enantiomers, the enantiomers can be separated using methods known to one skilled in the art: e.g. by formation and separation of diastereomeric salts or by HPLC over a chiral stationary phase such as a Regis Whelk-O1 (R,R) (10 μm) column, a Daicel ChiralCel OD-H (5-10 μm) column, or a Daicel ChiralPak IA (10 μm) or AD-H (5 μm) column. Typical conditions of chiral HPLC are an isocratic mixture of eluent A (ethanol, in presence or absence of an amine such as TEA, diethylamine) and eluent B (hexane), at a flow rate of 0.8 to 150 mL/min.
Experimental Section
Abbrevations (as used herein and in the description al aq. aqueous
Boc tø/t-Butoxycarbonyl
BSA Bovine serum albumine
CHO Chinese hamster ovary cone. Concentrated d Day(s)
DBU 1 ,8-Diazabicyclo[5.4.0]undec-7-ene
DCM Dichloromethane
DDQ 2,3-Dichloro-5,6-dicyano-1 ,4-benzoquinone
DIPEA Diisopropylethylamine
DMAP 4-Dimethylaminopyridine
DMF Λ/,Λ/-Dimethylformamide dppf diphenylphosphinoferrocene
EDC 1 -Ethyl-3-(3-dimethylaminopropyl)-carbodiimide eq Equivalent(s)
ES Electron spray
Et Ethyl ether diethylether
EtOAc Ethyl acetate
FCS Foatal calf serum
FLIPR Fluorescent imaging plate reader h Hour(s)
HATU (0-(7-azabenzotriazol-1 -yl)-1 ,1 ,3,3-tetramethyl-uronium hexafluorphoshate
HBSS Hank's balanced salt solution
HCI Hydrochloric acid
HEPES 4-(2-hydroxyethyl)-piperazine-1 -ethanesulfonic acid
HMPA Hexamethylphosphoramide
HOAt 1 -hydroxy-7-azabenzotriazole
HOBt 1 -hydroxy-benzotriazole
HPLC High performance liquid chromatography
KOtBu Potassium tert. butoxide
LC Liquid chromatography
M Molar(ity)
Me Methyl
MeCN Acetonitrile mCPBA mefa-chloroperoxybenzoic acid
MeOH Methanol min Minute(s)
MS Mass spectroscopy
NBS Λ/-bromosuccinimide
NFSI Λ/-Fluorobenzenesulfonimide prep. Preparative
PPTS Pyridinium 4-toluenesulfonate
PTSA p-Toluenesulfonic acid
RT Room temperature sat Saturated tR Retention time
TBTU 0-(Benzotriazol-1 -yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate
TEA Triethylamine
TFA trifluoroacetic acid THF Tetrahydrofuran
I-Chemistry
All temperatures are stated in °C. Compounds are characterized by 1H-NMR (300 MHz: Varian Oxford or 400 MHz: Bruker Avance); chemical shifts are given in ppm relative to the solvent used; multiplicities: s = singlet, d = doublet, t = triplet; p = pentuplet, hex = hexet, hept = heptet, m = multiplet, br = broad, coupling constants are given in Hz); by LC-MS (Finnigan Navigator with HP 1 100 Binary Pump and DAD, column: 4.6x50 mm, Zorbax SB-AQ, 5 μm, 120 A, using two conditions: basic: eluent A: MeCN, eluent B: cone. NH3 in water (1.0 mL/L), 5% to 95% CH3CN; acidic: eluent A: MeCN, eluent B: TFA in water (0.4 mL/L), 5% to 95% CH3CN), tR is given in min; by TLC (TLC-plates from Merck, Silica gel 60 F254); or by melting point. Compounds are purified by column chromatography on silica gel or by preparative HPLC (column: X-terra RP18, 50x19 mm, 5 μm, gradient: 10-95% MeCN in water containing 0.5 % of formic acid).
The following examples illustrate the preparation of pharmacologically active compounds of the invention but do not at all limit the scope thereof.
Preparation of precursors and intermediates:
A.1 Synthesis of thiazole-carboxylic acid derivatives
A.1.1 Synthesis of 3-chloro-2-oxo-propionic ester derivatives (general procedure)
Figure imgf000042_0001
A solution of the respective benzaldehyde derivative D-CHO (338 mmol, 1 .0 eq) and methyl dichloroacetate (338 mmol, 1.0 eq) in THF (100 mL) is added dropwise to a cold (-60<O) suspension of KOtBu (335 mmol, 1 .0 eq) in THF (420 mL). After 4 h the mixture is allowed to reach RT, stirred over night and concentrated in vacuo. DCM and ice-cold water are added, the layers are separated and the aqueous layer is extracted twice with DCM. The combined organic layers are washed with ice-cold water and brine, dried over MgSO4 and concentrated in vacuo to give the corresponding 3-chloro- 2-oxo-propionic acid methyl ester derivative which is used without further purification.
S-Chloro^-oxo-S-phenyl-propionic acid methyl ester prepared by reaction of benzaldehyde with methyl dichloroacetate.
S-Chloro^-oxo-S-m-tolyl-propionic acid methyl ester prepared by reaction of 3-methyl-benzaldehyde with methyl dichloroacetate.
3-Chloro-2-oxo-3-p-tolyl-propionic acid methyl ester prepared by reaction of 4-methyl-benzaldehyde with methyl dichloroacetate. 3-Chloro-3-(3-fluoro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3-fluoro-benzaldehyde with methyl dichloroacetate.
3-Chloro-3-(3,4-dichloro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3,4-dichloro-benzaldehyde with methyl dichloroacetate.
3-Chloro-3-(3,4-difluoro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3,4-difluoro-benzaldehyde with methyl dichloroacetate.
3-Chloro-3-(3,4-dimethyl-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3,4-dimethyl-benzaldehyde with methyl dichloroacetate.
3-Chloro-3-(2-fluoro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 2-fluoro-benzaldehyde with methyl dichloroacetate. 3-Chloro-3-(4-methoxy-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 4-methoxy-benzaldehyde with methyl dichloroacetate.
3-Chloro-3-(3-methoxy-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 3-methoxy-benzaldehyde with methyl dichloroacetate.
3-Chloro-3-(2-methoxy-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 2-methoxy-benzaldehyde with methyl dichloroacetate.
3-Chloro-3-(4-fluoro-phenyl)-2-oxo-propionic acid methyl ester prepared by reaction of 4-fluoro-benzaldehyde with methyl dichloroacetate.
3-Chloro-2-oxo-3-(3-trifluoromethyl-phenyl)-propionic acid methyl ester prepared by reaction of 3-trifluoromethyl-benzaldehyde with methyl dichloro-acetate. 3-Chloro-2-oxo-3-(4-trifluoromethyl-phenyl)-propionic acid methyl ester prepared by reaction of 4-trifluoromethyl-benzaldehyde with methyl dichloroacetate. A.1.2 Synthesis of 2-methyl-thiazole-4-carboxylic acid methyl ester derivatives (general procedure)
Figure imgf000044_0001
A solution of thioacetamide (132 mmol, 1.0 eq) in MeCN (250 ml.) is added to a mixture of the respective 3-chloro-2-oxo-propionic acid methyl ester derivative
(132 mmol, 1 .0 eq) and molecular sieves (4A, 12 g) in MeCN (60 ml_). After stirring for
5 h the mixture is cooled in an ice-bath and the obtained precipitate is filtered off. The residue is washed with cold MeCN, dried, dissolved in MeOH (280 ml.) and stirred at
50°C for 6 h. The solvents are removed in vacuo to give the corresponding 2-methyl- thiazole-4-carboxylic acid methyl ester derivatives.
2-Methyl-5-m-tolyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-2-oxo-3-m-tolyl-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.94 min; [M+H]+ = 248.0.
2-Methyl-5-p-tolyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-2-oxo-3-p-tolyl-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.93 min; [M+H]+ = 248.02.
5-(3-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.91 min; [M+H]+ = 252.1. 5-(4-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(4-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. 1H-NMR (CDCI3): δ = 2.75 (s, 3H); 3.84 (s, 3H); 7.10 (m, 2H); 7.47 (m, 2H).
5-(2-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(2-fluoro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.90 min; [M+H]+ = 251.99.
2-Methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-trifluoromethyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.99 min; [M+H]+ = 301.99. 2-Methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(4-trifluoromethyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.99 min; [M+H]+ = 301.99
2-Methyl-5-(3,4-dimethyl-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3,4-dimethyl-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.96 min; [M+H]+ = 262.34.
2-Methyl-5-(3,4-dichloro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3,4-dichloro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.99 min; [M+H]+ = 302.22. 2-Methyl-5-(3,4-difluoro-phenyl)-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3,4-difluoro-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.92 min; [M+H]+ = 270.29.
5-(4-Methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(4-methoxy-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.90 min; [M+H]+ = 263.93.
5-(3-Methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(3-methoxy-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.90 min; [M+H]+ = 263.87.
5-(2-Methoxy-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-(2-methoxy-phenyl)-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.88 min; [M+H]+ = 264.05.
5-Phenyl-2-methyl-thiazole-4-carboxylic acid methyl ester prepared by reaction of 3-chloro-3-phenyl-2-oxo-propionic acid methyl ester with thioacetamide. LC-MS: tR = 0.88 min; [M+H]+ = 234.23. A.1.3 Synthesis of thiazole-4-carboxylic acid derivatives (general procedure)
Figure imgf000045_0001
A solution of the respective thiazole-4-carboxylic acid methyl ester (96.2 mmol) in a mixture of THF (150 mL) and MeOH (50 mL) is treated with 1 M aq. NaOH (192 mL).
After stirring for 3 h a white suspension is formed and the organic volatiles are removed in vacuo. The remaining mixture is diluted with water (100 mL), cooled in an ice-bath and acidified (pH = 3-4) by addition of 1 M aq. HCI. The suspension is filtered and the residue is washed with cold water. After drying the corresponding 2-methyl-thiazole-4- carboxylic acid derivative is obtained.
2-Methyl-5-m-tolyl-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-m-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.83 min; [M+H]+ = 233.99.
2-Methyl-5-p-tolyl-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-p-tolyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.83 min; [M+H]+ = 234.0. 5-(3-Fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid prepared by saponification of 5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.82 min; [M+H]+ = 238.1.
S-^-Fluoro-phenylJ^-methyl-thiazole-^carboxylic acid prepared by saponification of 5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carboxylic acid methyl ester. 1 H-NMR (DMSOd6): δ = 2.67 (s, 3H); 7.27 (m, 2H); 7.53 (m, 2H); 12.89 (br.s, 1 H).
2-Methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-(3-trifluoromethyl-phenyl)-thiazole- 4-carboxylic acid methyl ester. LC-MS: tR = 0.88 min; [M+H]+ = 287.99. 2-Methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-(4-trifluoromethyl-phenyl)-thiazole- 4-carboxylic acid methyl ester. LC-MS: tR = 0.90 min; [M+H]+ = 287.99.
2-Methyl-5-(3,4-dimethyl-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-(3,4-dimethyl-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.97 min; [M+H]+ = 382.38.
2-Methyl-5-(3,4-dichloro-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-(3,4-dichloro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.88 min; [M+H]+ = 288.22.
2-Methyl-5-(3,4-difluoro-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-(3,4-difluoro-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.82 min; [M+H]+ = 256.25.
2-Methyl-5-(2-methoxy-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-(2-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.78 min; [M+H]+ = 249.98.
2-Methyl-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-(3-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.80 min; [M+H]+ = 250.04.
2-Methyl-5-(4-methoxy-phenyl)-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-(4-methoxy-phenyl)-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.80 min; [M+H]+ = 250.04.
2-Methyl-5-phenyl-thiazole-4-carboxylic acid prepared by saponification of 2-methyl-5-phenyl-thiazole-4-carboxylic acid methyl ester. LC-MS: tR = 0.78 min; [M+H]+ = 220.01.
A.1.4 Synthesis of 2-methyl-4-p-tolyl-thiazole-5-carboxylic acid
A mixture of 4-methylbenzoyl acetate (5.52 mmol), sulfuryl chloride (5.52 mmol) in chloroform (3.3 ml) was held at reflux overnight. After cooling down to room temperature the organic phase was washed with water, dried over MgSO4 and concentrated under reduced pressure. The crude product was dissolved in THF (12.0 ml) and thioacetamide (6.75 mmol) and solid NaHCO3 (6.07 mmol) were added. The mixture was heated to reflux for 6 h and then it was filtered. The solvent was removed and the crude product purified by column chromatography using heptane/ethyl acetate as eluent system to provide 2-methyl-4-p-tolyl-thiazole- 5-carboxylic acid methyl ester (2.67 mmol).
2-Methyl-4-p-tolyl-thiazole-5-carboxylic acid methyl ester (2.67 mmol) and solid KOH (5.35 mmol) were dissolved in ethanol (1 .04 mL) and water (0.26 mL) and heated under reflux for 3 hours. After cooling, the solvent was evaporated under reduced pressure and ice water was added to the residue, followed by washing with hexane. The aqueous layer was acidified with 1 N aq. HCI and the crystals thus precipitated were collected by filtration, washed with water and then dried to provide 2-methyl- 4-p-tolyl-thiazole-5-carboxylic acid. LC-MS: tR = 0.83 min; [M+H]+ = 234.02. A.2 Synthesis of 2-methyl-oxazole-4-carboxylic acid derivatives
A.2.1 Synthesis of 2-acetylamino-3-oxo-propionic acid methyl ester derivatives (general procedure)
Figure imgf000048_0001
A solution of the respective 3-oxo-propionic acid methyl ester derivative (4.8 mmol, 1.0 eq.) in glacial acetic acid (1 .9 mL) was cooled to 109C and at this temperature was added a solution of NaNO2 (5.6 mmol, 1 .16 eq.) in water (0.68 mL). After the addition was complete (15 min), the solution was allowed to warm to room temperature and stirred for 2 h. Then the solution was poured into water (10 mL) and after a few minutes crystals begun to appear. This suspension was cooled in an ice-bath and crystals were collected by filtration. The cake was washed several times with cold water and the water was removed by the azeotrope of toluene-water in vacuo to give 2-hydroxyimino- 3-oxo-propionic acid methyl ester derivatives which were dissolved in a mixture of acetic anhydride (1 .375 mL) and glacial acetic acid (1 .8 mL). To this solution was added sodium acetate (0.296 mmol, 0.06 eq.) and HgCI2 (0.01 mmol, 0.002 eq.). The mixture was refluxed for 1 h, then cooled to room temperature and filtered. The solid was rinsed with ether, the organic filtrate was recovered, washed 3 times with water and one time with 1 M aq. K2CO3 The organic layer was dried over MgSO4, filtered and concentrated. The crude products were purified by flash chromatography to afford the corresponding 2-acetylamino-3-oxo-propionic acid methyl ester derivatives.
2-Acetylamino-3-oxo-3-(3-trifluoromethyl-phenyl)-propionic acid methyl ester prepared according to general procedure A.2.1 from 3-oxo-(3-trifluoromethyl-phenyl)- propionic acid methyl ester.
2-Acetylamino-3-oxo-3-m-tolyl-propionic acid methyl ester prepared according to general procedure A.2.1 from 3-oxo-3-m-tolyl-propionic acid methyl ester.
2-Acetylamino-3-oxo-3-p-tolyl-propionic acid methyl ester prepared according to general procedure A.2.1 from 3-oxo-3-p-tolyl-propionic acid methyl ester. 2-Acetylamino-3-(4-fluoro-phenyl)-3-oxo-propionic acid methyl ester prepared according to general procedure A.2.1 from 3-oxo-3-(4-fluoro-phenyl)- propionic acid methyl ester.
2-Acetylamino-3-(4-methoxy-phenyl)-3-oxo-propionic acid methyl ester prepared according to general procedure A.2.1 from 3-oxo-3-(4-methoxy-phenyl)- propionic acid methyl ester.
A.2.2 Synthesis of 2-methyl-oxazole-4-carboxylic acid derivatives (general procedure)
Figure imgf000049_0001
A solution of the respective 2-acetylamino-3-oxo-propionic acid methyl ester derivative (0.63 mmol, 1 .0 eq.) in chloroform (0.4 ml.) was cooled to O9C in an ice/NaCI bath. SOCI2 (0.88 mmol, 1 .4 eq.) was added to the stirred solution and the temperature was maintained at O9C for 30 minutes. Then the solution was stirred and refluxed for one hour. Another 0.25 eq. of SOCI2 was added and the reaction mixture was refluxed for another hour. The excess SOCI2 was quenched with 1 M aq. K2CO3. The aqueous layer was extracted twice with ether. The combined organic phases were washed once with water and dried over MgSO4, filtered and concentrated yielding the corresponding 2-methyl-oxazole-4-carboxylic acid methyl ester derivative. The respective 2-methyl- oxazole-4-carboxylic acid methyl ester derivative was dissolved in a mixture of ethanol (0.7 ml) and 2N aq. NaOH (0.7 ml_, 2.5 eq.). The mixture was stirred at RT for 2 hours.
The reaction mixture was washed once with ether and this organic layer was discarded. The aqueous layer was then acidified with cone. HCI and extracted twice with ether. Both organic layers were combined, dried over MgSO4 and concentrated in vacuo to afford the corresponding 2-methyl-oxazole-4-carboxylic acid derivatives. 2-Methyl-5-m-tolyl-oxazole-4-carboxylic acid prepared according to general procedure A.2.2 from 2-acetylamino-3-oxo-3-m-tolyl- propionic acid methyl ester LC-MS: tR = 0.51 min; [M-H]+ = 216.33.
2-Methyl-5-(3-trifluoromethyl-phenyl)-oxazole-4-carboxylic acid prepared according to general procedure A.2.2 from 2-acetylamino-3-oxo-3- (3-trifluoromethyl-phenyl)-propionic acid methyl ester. LC-MS: tR = 0.55 min; [M-H]+ = 270.24.
2-Methyl-5-p-tolyl-oxazole-4-carboxylic acid prepared according to general procedure A.2.2 from 2-acetylamino-3-oxo-3-p-tolyl- propionic acid methyl ester. LC-MS: tR = 0.55 min; [M-H]+ = 216.34.
5-(4-Fluoro-phenyl)-2-methyl-oxazole-4-carboxylic acid prepared according to general procedure A.2.2 from 2-acetylamino-3-(4-fluoro-phenyl)- 3-oxo-propionic acid methyl ester. LC-MS: tR = 0.49 min; [M-H]+ = 220.30. 5-(4-Methoxy-phenyl)-2-methyl-oxazole-4-carboxylic acid prepared according to general procedure A.2.2 from 2-acetylamino-3-(4-methoxy- phenyl)-3-oxo-propionic acid methyl ester. LC-MS: tR = 0.77 min; [M+H]+ = 234.31 .
5-(3-Methoxy-phenyl)-2-methyl-oxazole-4-carboxylic acid prepared according to general procedure A.2.2 from 2-acetylamino-3-(3-methoxy- phenyl)-3-oxo-propionic acid methyl ester. LC-MS: tR = 0.49 min; [M+H]+ = 232.30.
A.3 Biphenyl-2-carboxylic acid derivatives
The following biphenyl-2-carboxylic acid derivatives are commercially available:
Biphenyl-2-carboxylic acid; 4'-Methyl-biphenyl-2-carboxylic acid; 3'-Methyl-biphenyl-2-carboxylic acid;
3',4'-Dimethyl-biphenyl-2-carboxylic acid; 4'-Methoxy-biphenyl-2-carboxylic acid; 3'-Methoxy-biphenyl-2-carboxylic acid; 4'-Fluoro-biphenyl-2-carboxylic acid. A.4 Synthesis of 4-{[acyl-amino]-methyl}-thiazolidine derivatives
Figure imgf000050_0001
A.4.1 Synthesis of 4-{[acyl-amino]-methyl}-thiazolidine-3-carboxylic acid tert- butyl ester derivatives (general procedure) To a solution of the respective carboxylic acid R1COOH, wherein R1 is as defined for formula (I), (4.6 mmol, 1.0 eq.), 4-aminomethyl-thiazolidine-3-carboxylic acid tert-butyl ester (4.6 mmol, 1 .0 eq.) and DMAP (2.3 mmol, 1.0 eq.) in DCM (25 ml.) was added under stirring solid EDC (4.7 mmol, 1 .02 eq.). Stirring continued over night. Then sat. aq. NaHCO3 solution (6 ml.) was added to the reaction mixture and stirring continued for 30 min. The organic phase was separated, the solvent was stripped off yielding the crude corresponding 4-{[acyl-amino]-methyl}-thiazolidine-3-carboxylic acid tert-butyl ester derivative.
The following intermediates were synthesized according to general procedure A.4.1 from commercially available (R)-4-aminomethyl-thiazolidine-3-carboxylic acid tert-butyl ester and the respective carboxylic acid R1COOH, which is commercially available or synthesized according to methods described above:
Figure imgf000051_0001
Figure imgf000052_0001
A.4.2 Synthesis of 4-{[acyl-amino]-methyl}-thiazolidine derivatives
The respective 4-{[acyl-amino]-methyl}-thiazolidine-3-carboxylic acid tert-butyl ester derivative (0.15 mmol, 1 .0 eq.) was dissolved in a mixture of dry MeOH (0.33 ml.) and 4 M HCI in dioxane (0.75 ml_, 20 eq.). After shaking for 2 h the solvent was evaporated and the residue treated with dry MeOH (1 mL) followed by evaporation and drying under vacuo for 14 h to provide the corresponding 4-{[acyl-amino]-methyl}-thiazolidine derivative hydrochloride.
Preparation of Examples (general procedure 1) The corresponding thiazole-carboxylic acid derivative (Intermediate according to method A.1 ), 2-methyl-oxazole-4-carboxylic acid derivative (Intermediate according to method A.2), or biphenyl-2-carboxylic acid derivative (Intermediate according to method A.3), respectively, (0.15 mmol, 1.0 eq.) was dissolved in a mixture of dry DMF (1.0 mL) and DIPEA (0.58 mmol, 3.9 eq.) under stirring. Solid HATU (0.15 mmol, 1 .0 eq.) was added and stirring was allowed for 10 min. This solution was added to the respective crude 4-{[acyl-amino]-methyl}-thiazolidine derivative hydrochloride (Intermediate according to method A.4) and the mixture was stirred over night. The DMF was evaporated under vacuum and the crude product purified by prep. HPLC to provide the final compound. The following Examples given in table 1 were synthesized according to the general procedure 1 given above:
Table 1 :
Figure imgf000052_0002
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
Figure imgf000057_0001
Figure imgf000058_0001
Figure imgf000059_0001
Figure imgf000060_0002
A.5 Synthesis of 3-acyl-(4-aminomethyl)-thiazolidine derivatives
Figure imgf000060_0001
A.5.1 Synthesis of 4-[(2,2,2-trifluoro-acetylamino)-methyl]-thiazolidine-3- carboxylic acid tert-butyl ester
To a solution of (R)-4-Aminomethyl-thiazolidine-3-carboxylic acid tert-butyl ester (19 mmol) in dry THF (56 mL) was added slowly ethyl trifluoroacetate (22.8 mmol, 1.2 eq)). The reaction mixture was stirred at rt for 20 h and concentrated to yield the crude title compound which was used for the next step without further purification. LC-MS: tR = 0.94 min; [M+H]+ = 315.04.
A.5.2 Synthesis of 2,2,2-trifluoro-Λ/-thiazolidin-4-ylmethyl-acetamide (trifluoroacetic acid salt) To a cold (O9C) solution of 4-[(2,2,2-trifluoro-acetylamino)-methyl]-thiazolidine-3- carboxylic acid tert-butyl ester (19 mmol) in dry DCM (10 mL) was added dropwise TFA (133 mmol, 7 eq). The reaction mixture was stirred for 20 h and concentrated in vacuo to give the title compound. LC-MS: tR = 0.24 min; [M+H]+ = 214.99. A.5.3 Synthesis of 3-acyl-(4-aminomethyl)-thiazolidine derivatives (general procedure)
A solution of the respective carboxylic acid A-COOH (4.6 mmol, 1 eq), TBTU (4.6 mmol, 1 eq), DIPEA (23 mmol, 5 eq) in dry DMF (15 ml.) was stirred at rt for 30 min. Then, was added 2,2,2-trifluoro-Λ/-thiazolidin-4-ylmethyl-acetamide (trifluoroacetic acid salt) (4.6 mmol, 1 .0 eq.) in dry DMF (0.5 ml_). Stirring was continued over night. The reaction mixture was partitioned between sat. aq. NaHCO3 solution/ EtOAc. The organic phase was washed with brine, dried (MgSO4), filtered and concentrated to give the corresponding N-(thiazolidin-4-ylmethyl)-2,2,2-trifluoro-acetamide derivative which was used for the next step without further purification. To a solution of the above product (4.6 mmol) in dry MeOH (32 ml.) was added sat. K2CO3 (32 ml_). The reaction mixture was stirred at rt for 20 h. Diethyl ether was added, and the organic phase was washed with 25% HCI, 1 N HCI. The aqueous phase was basified with 30% NaOH and extracted with DCM. The combined organic extracts were washed with brine, dried (MgSO4), filtered and concentrated to give the corresponding 3-acyl-(4-aminomethyl)- thiazolidine derivative which was used for the next step without further purification.
The following intermediates were synthesized according to general procedure A.5.3 from commercially available (R)-4-aminomethyl-thiazolidine-3-carboxylic acid tert-butyl ester and the respective carboxylic acid A-COOH, which is commercially available or synthesized according to methods described above:
Figure imgf000061_0001
Preparation of Examples (general procedure 2)
The corresponding acid R1COOH (0.15 mmol, 1.0 eq.) was dissolved in a mixture of dry DMF (1 .0 ml.) and DIPEA (0.75 mmol, 5 eq.) under stirring. Solid TBTU (0.15 mmol, 1.0 eq.) was added and stirring was allowed for 15 min. Then was added a solution of the respective 3-acyl-(4-aminomethyl)-thiazolidine derivative (0.15 mmol, 1 eq) (Intermediate according to method A.5.3) in dry DMF (0.5 ml.) and the mixture was stirred over night. The DMF was evaporated under vacuum and the crude product purified by prep. HPLC to provide the final compound.
The following Examples given in table 2 were synthesized according to the general procedure 2 given above:
Table 2:
Figure imgf000062_0001
Figure imgf000063_0001
Figure imgf000064_0001
Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Example 164:
2-Trifluoromethyl-benzofuran-4-carboxylic acid [3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide a) 2-lodo-benzofuran-4-carboxylic acid To a cold (-78 °C) solution of benzofuran-4-carboxylic acid (100 mg) in dry diethyl ether (1.2 ml_), was added dropwise tert-butyl lithium (1.7 M in pentane, 0.8 ml_, 2.2 eq). The reaction mixture was stirred at -789C for 30 min. under nitrogen, then a solution of iodine (172.2 mg, 1 .2 eq) in ether (1.9 ml.) was added dropwise. The reaction was stirred at -78^ for 30 min. and allowed to warm to rt. The reaction mixture was partitioned between sat. NH4CI and diethyl ether, the aqueous phase was extracted once again with diethyl ether. The combined organic extracts were washed with sat. sodium thiosulfate, water, dried (Na2SO4), filtered and concentrated to yield a crude brown solid. FC (DCM/ MeOH: 99/1 to 97/3) afforded the title compound as a pink solid (40 mg, 23%). LC-MS: tR = 0.89 min; [M+H]+ = 288.99. b) 2-lodo-benzofuran-4-carboxylic acid [3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide
A solution of 2-iodo-benzofuran-4-carboxylic acid (29.5 mg), TBTU (34 mg 1 eq), DIPEA (0.087 ml_, 5 eq) in dry DMF (0.325 ml.) was stirred at rt for 15 min. Then, was added (4-Aminomethyl-thiazolidin-3-yl)-(2-methyl-5-m-tolyl-thiazol-4-yl)-methanone (34 mg, 1.0 eq.) in dry DMF (0.325 ml_). Stirring was continued over night. The reaction mixture was partitioned between sat. aq. NaHCO3 solution/ EtOAc. The organic phase was washed with brine, dried (MgSO4), filtered and concentrated to give 2-iodo- benzofuran-4-carboxylic acid [3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-thiazolidin-4- ylmethyl]-amide (57 mg, 93%) which was used for the next step without further purification. LC-MS: tR = 0.89 min; [M+H]+ = 288.99. c) 2-Trifluoromethyl-benzofuran-4-carboxylic acid [3-(2-methyl-5-m-tolyl-thiazole- 4-carbonyl)-thiazolidin-4-ylmethyl]-amide
A mixture of 2-iodo-benzofuran-4-carboxylic acid [3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide (57 mg), copper (I) iodide (91 mg, 5 eq), methyl 2,2-difluoro-2-(fluorosulfonyl)acetate (0.08 mL, 6.5 eq), HMPA (0.17 mL, 10 eq) in dry DMF (2.5 mL) was stirred at 809C for 16 hours under nitrogen. After cooling to rt, the reaction mixture was partitioned between water and EtOAc, the organic phase was washed again with water, dried (MgSO4), filtered and concentrated in vacuo to yield a crude yellow-orange oil. FC (AIO3, EtOAc/ n-heptane: 7/3) gave the title compound (4.2 mg, 8%) as a white solid. LC-MS: tR = 1 .08 min; [M+H]+ = 546.22.
Il-Bioloqical assays
In vitro assay
The orexin receptor antagonistic activity of the compounds of formula (I) is determined in accordance with the following experimental method.
Experimental method:
Intracellular calcium measurements:
Chinese hamster ovary (CHO) cells expressing the human orexin-1 receptor and the human orexin-2 receptor, respectively, are grown in culture medium (Ham F-12 with L-Glutamine) containing 300 μg/ml G418, 100 U/ml penicillin, 100 μg/ml streptomycin and 10 % inactivated fetal calf serum (FCS). The cells are seeded at 80'0OO cells / well into 96-well black clear bottom sterile plates (Costar) which have been precoated with 1 % gelatine in Hanks' Balanced Salt Solution (HBSS). All reagents are from Gibco BRL. The seeded plates are incubated overnight at 37°C in 5% CO2.
Human orexin-A as an agonist is prepared as 1 mM stock solution in methanol: water (1 :1 ), diluted in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES for use in the assay at a final concentration of 10 nM.
Antagonists are prepared as 10 mM stock solution in DMSO, then diluted in 96-well plates, first in DMSO, then in HBSS containing 0.1 % bovine serum albumin (BSA) and 2 mM HEPES.
On the day of the assay, 100 μl of loading medium (HBSS containing 1% FCS, 2 mM HEPES, 5 mM probenecid (Sigma) and 3 μM of the fluorescent calcium indicator fluo-3 AM (1 mM stock solution in DMSO with 10% pluronic acid) (Molecular Probes) is added to each well.
The 96-well plates are incubated for 60 min at 37° C in 5% CO2. The loading solution is then aspirated and cells are washed 3 times with 200 μl HBSS containing 2.5 mM probenecid, 0.1% BSA, 2 mM HEPES. 100 μl of that same buffer is left in each well. Within the Fluorescent Imaging Plate Reader (FLIPR, Molecular Devices), antagonists are added to the plate in a volume of 50 μl, incubated for 20 min and finally 100 μl of agonist is added. Fluorescence is measured for each well at 1 second intervals, and the height of each fluorescence peak is compared to the height of the fluorescence peak induced by 10 nM orexin-A with buffer in place of antagonist. For each antagonist, IC50 value (the concentration of compound needed to inhibit 50 % of the agonistic response) is determined. Antagonistic activities of compounds are in the nanomolar range below 1000 nM with respect to the OXi and/or the OX2 receptor. Antagonistic activities (IC50 values) of 162 exemplified compounds are in the range of 0.9 - 7245 nM with an average of 181 nM with respect to the 0X1 receptor. IC50 values of 164 exemplified compounds are in the range of 0.7-1285 nM with an average of 96 nM with respect to the 0X2 receptor. Antagonistic activities of selected compounds are displayed in Table 2.
Table 2
Figure imgf000071_0001

Claims

Claims
1. A compound of formula (I)
Figure imgf000072_0001
(i) wherein
A represents
Figure imgf000072_0002
X represents O, or S; R2 represents (d-4)alkyl;
D represents aryl, which is unsubstituted, mono-, di, or tri-substituted wherein the substituents are independently selected from the group consisting of (d-4)alkyl, (Ci-4)alkoxy, trifluoromethyl, and halogen;
R1 represents aryl, wherein the aryl group is selected from the group consisting of a phenyl-, a naphthyl-, a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro- benzo[1 ,4]dioxinyl-, a 4H-benzo[1 ,3]dioxinyl, a 2H-chromenyl-, a chromanyl-, a 3,4- dihydro-2H-benzo[1 ,4]oxazinyl-, and a 3-biphenyl group, wherein said groups are unsubstituted, mono-, di, or tri-substituted wherein the substituents are independently selected from the group consisting of (C1-4)alkyl, (Ci-4)alkoxy, trifluoromethyl, halogen and nitro; or R1 represents heteroaryl, which is unsubstituted, mono-, di, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci- 4)alkyl, (Ci_4)alkoxy, halogen, hydroxy-(Ci-4)alkyl, and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
2. A compound of formula (I) according to claim 1 , wherein the stereogenic center at the thiazolidine ring is in (R)-configuration.
3. A compound according to claims 1 or 2, wherein A represents
Figure imgf000073_0001
or a pharmaceutically acceptable salt thereof.
4. A compound according to any one of claims 1 to 3, wherein X represents S; or a pharmaceutically acceptable salt thereof.
5. A compound according to claims 1 or 2, wherein A represents
Figure imgf000073_0002
or a pharmaceutically acceptable salt thereof.
6. A compound according to any one of claims 1 to 5, wherein D represents unsubstituted, mono-, di-, or tri-substituted phenyl, wherein the substituents are independently selected from the group consisting of (d-4)alkyl, (d-4)alkoxy, trifluoromethyl, and halogen; or a pharmaceutically acceptable salt thereof.
7. A compound according to any one of claims 1 to 6, wherein
R1 represents aryl, wherein the aryl group is selected from the group consisting of a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, a 4H-benzo[1 ,3]dioxinyl, a 2H-chromenyl-, a chromanyl-, and a 3,4-dihydro-2H- benzo[1 ,4]oxazinyl group, wherein said groups are unsubstituted, mono-, or di- substituted wherein the substituents are independently selected from the group consisting of (C1 -4)alkyl, (Ci-4)alkoxy and halogen; or R1 represents heteroaryl, which is unsubstituted, mono-, di, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci- 4)alkyl, (d.4)alkoxy, halogen, hydroxy-(Ci_4)alkyl, and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
8. A compound according to any one of claims 1 to 7, wherein R1 represents heteroaryl, wherein said hetereroaryl is selected from the group consisting of thienyl, thiazolyl, pyrazolyl, pyridyl, indolyl, benzofuranyl, indazolyl, benzoxazolyl, benzisoxazolyl, benzothiazolyl, benzoxadiazolyl, benzothiadiazolyl, imidazo[1 ,2-a]pyridyl, imidazo[2,1 -b]thiazolyl, benzoisothiazolyl, and pyrrolo[2,1 - b]thiazolyl, wherein said groups are unsubstituted, mono-, di-, or tri-substituted, wherein the substituents are independently selected from the group consisting of (Ci-4)alkyl, (Ci-4)alkoxy, halogen, hydroxy-(d-4)alkyl, and trifluoromethyl; or a pharmaceutically acceptable salt thereof.
9. A compound according to any one of claims 1 to 7, wherein
R1 represents aryl, wherein the aryl group is selected from the group consisting of a 2,3-dihydro-benzofuranyl-, a benzo[1 ,3]dioxolyl-, a 2,3-dihydro-benzo[1 ,4]dioxinyl-, a 4H-benzo[1 ,3]dioxinyl, a 2H-chromenyl-, a chromanyl-, and a 3,4-dihydro-2H- benzo[1 ,4]oxazinyl group, wherein said groups are unsubstituted, mono-, or di- substituted wherein the substituents are independently selected from the group consisting of (C1 -4)alkyl, (Ci_4)alkoxy and halogen; or a pharmaceutically acceptable salt thereof.
10. A compound according to claim 1 selected from the group consisting of:
Benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(2-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(3-methoxy-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; Benzofuran-4-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl-phenyl)-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(3,4-difluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(2-methoxy-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl-phenyl)-oxazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-oxazole-4-carbonyl)-thiazolidin-
4-ylmethyl]-amide; Benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-oxazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid [(R)-3-(2-methyl-4-p-tolyl-thiazole-5-carbonyl)-thiazolidin-
4-ylmethyl]-amide; Benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-oxazole-4-carbonyl)-thiazolidin-
4-ylmethyl]-amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(3,4-dichloro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; Benzofuran-4-carboxylic acid {(R)-3-[5-(4-methoxy-phenyl)-2-methyl-oxazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid [(R)-3-(4'-methyl-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(3',4'-dimethyl-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(3'-methyl-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(3'-methoxy-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide; Benzofuran-4-carboxylic acid [(R)-3-(4'-fluoro-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(4'-methoxy-biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
2,3-Dihydro-benzo[1 ,4]dioxine-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-phenyl-thiazole-4-carbonyl)-thiazolidin-
4-ylmethyl]-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-5-phenyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[2-methyl-5-(4-trifluoromethyl-phenyl)- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(3,4-dimethyl-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(2-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(3-methoxy-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl-phenyl)- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(3,4-difluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-thiazole-4-carbonyl)-thiazolidin- 4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(2-methoxy-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl-phenyl)- oxazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-oxazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-oxazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-4-p-tolyl-thiazole-5-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-oxazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(3,4-dichloro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid {(R)-3-[5-(4-methoxy-phenyl)-2-methyl-oxazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(4'-methyl-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(3',4'-dimethyl-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
Benzofuran-4-carboxylic acid {(R)-3-[2-methyl-5-(4-trifluoromethyl-phenyl)-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(3'-methyl-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(3'-methoxy-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(4'-fluoro-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide; 1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(4'-methoxy-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
3-Bromo-N-{(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-thiazolidin-4- ylmethylj-benzamide;
1 -Methyl-1 H-indole-2-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
4-Bromo-thiophene-2-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Bromo-pyridine-2-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; 2,3-Dihydro-benzo[1 ,4]dioxine-5-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
Benzofuran-4-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)-thiazolidin-4-ylmethyl]- amide;
Benzofuran-4-carboxylic acid {(R)-3-[5-(3-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
N-[(R)-3-(Biphenyl-2-carbonyl)-thiazolidin-4-ylmethyl]-3-bromo-benzamide;
1 -Methyl-1 H-indole-2-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
4-Bromo-thiophene-2-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)-thiazolidin-4- ylmethyl]-amide;
6-Bromo-pyridine-2-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)-thiazolidin-4-ylmethyl]- amide; Benzofuran-4-carboxylic acid {(R)-3-[5-(3,4-dimethyl-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Naphthalene-1 -carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; 5-tert-Butyl-2-methyl-2H-pyrazole-3-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2,3-Dihydro-benzofuran-7-carboxylic acid {(R)-3[5-(4-fluoro-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 2,4-Dimethyl-thiazole-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Λ/-{(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-3- nitro-benzamide;
Benzo[/?]thiophene-2-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
2-Methyl-benzooxazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; lmidazo[1 ,2-a]pyridine-3-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
2-Methyl-imidazo[1 ,2-a]pyridine-3-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2,3-Dimethyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
3,4-Dihydro-2H-benzo[1 ,4]oxazine-5-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-
4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
4-Methyl-3,4-Dihydro-2H-benzo[1 ,4]oxazine-5-carboxylic acid [(R)-3-(2-methyl-5-m- tolyl-thiazole-4-carbonyl)-thiazolidin-4-ylmethyl]-amide; Chroman-5-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-thiazolidin-4- ylmethyl]-amide;
Chroman-8-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)-thiazolidin-4- ylmethyl]-amide;
3,4-Dihydro-2H-benzo[1 ,4]oxazine-8-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole- 4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
4-Methyl-3,4-Dihydro-2H-benzo[1 ,4]oxazine-8-carboxylic acid [(R)-3-(2-methyl-5-m- tolyl-thiazole-4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
Benzo[c/]isoxazole-3-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide; Benzotcflisothiazole-S-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
1 -Methyl-1 H-indazole-3-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide; 2,3-Dihydro-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2,3-Dihydro-benzo[1 ,4]dioxine-5-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2-Methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; lmidazo[1 ,2-a]pyridine-3-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Methyl-imidazo[1 ,2-a]pyridine-3-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 2,3-Dimethyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
3,4-Dihydro-2H-benzo[1 ,4]oxazine-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
4-Methyl-3,4-dihydro-2H-benzo[1 ,4]oxazine-5-carboxylic acid {(R)-3-[5-(4-fluoro- phenyl)-2-methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
Chroman-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide;
Chroman-8-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4-carbonyl]- thiazolidin-4-ylmethyl}-amide; 3,4-Dihydro-2H-benzo[1 ,4]oxazine-8-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
4-Methyl-3,4-dihydro-2H-benzo[1 ,4]oxazine-8-carboxylic acid {(R)-3-[5-(4-fluoro- phenyl)-2-methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2,3-Dihydro-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole- 4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzooxazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
Benzooxazole-7-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; 2-Methyl-benzooxazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2-Methyl-benzooxazole-7-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide; Benzothiazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
Benzothiazole-7-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
7-Chloro-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
7-Chloro-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
7-Fluoro-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide; 7-Fluoro-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Pyrrolo[2,1 -£>]thiazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
Pyrrolo[2,1 -£>]thiazole-7-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-pyrrolo[2,1 -ιfc>]thiazole-7-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Methyl-pyrrolo[2,1 -/?]thiazole-7-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 7-Chloro-2-methoxy-2,3-dihydro-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m- tolyl-thiazole-4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
7-Chloro-2-methoxy-2,3-dihydro-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro- phenyl)-2-methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Chloro-benzothiazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2-Chloro-benzothiazole-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzothiazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide; Benzothiazole-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide;
Benzo[2,1 ,3]thiadiazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; Benzo[2,1 ,3]thiadiazole-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
7-Trifluoromethyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
7-Trifluoromethyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
3-Methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide;
3-Methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-4- carbonyl]-thiazolidin-4-ylmethyl}-amide; Benzo[2,1 ,3]oxadiazole-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
Benzo[2,1 ,3]oxadiazole-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl-thiazole-
4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Hydroxymethyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2-Hydroxymethyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4-carbonyl)- thiazolidin-4-ylmethyl]-amide; 5-Chloro-2-methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
7-Chloro-2-methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
7-Fluoro-2-methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2-Methyl-7-trifluoromethyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl- thiazole-4-carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Chloro-2-methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; 6-Fluoro-2-methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
2-Methyl-6-trifluoromethyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl- thiazole-4-carbonyl)-thiazolidin-4-ylmethyl]-amide; 5-Chloro-2-methyl-benzofuran-4-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
7-Chloro-2-methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
7-Fluoro-2-methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Methyl-7-trifluoromethyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Chloro-2-methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 6-Fluoro-2-methyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Methyl-6-trifluoromethyl-benzofuran-4-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
2-Trifluoromethyl-benzofuran-4-carboxylic acid [3-(2-methyl-5-m-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; θ-Methyl-imidazo^J -blthiazole-S-carboxylic acid [(R)-3-(2-methyl-5-phenyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-thiazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[2-methyl-5-(4-trifluoromethyl- phenyl)-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(3-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(3,4-dimethyl-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(2-fluoro-phenyl)-2-methyl- thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(3-methoxy-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl- phenyl)-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(3,4-difluoro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -/?]thiazole-5-carboxylic acid {(R)-3-[5-(2-methoxy-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[2-methyl-5-(3-trifluoromethyl- phenyl)-oxazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide ; θ-Methyl-imidazo^J -blthiazole-S-carboxylic acid [(R)-3-(2-methyl-5-p-tolyl-oxazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(4-fluoro-phenyl)-2-methyl- oxazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(2-methyl-4-p-tolyl-thiazole-5- carbonyl)-thiazolidin-4-ylmethyl]-amide; θ-Methyl-imidazo^J -bJthiazole-S-carboxylic acid [(R)-3-(2-methyl-5-m-tolyl-oxazole-4- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(3,4-dichloro-phenyl)-2- methyl-thiazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid {(R)-3-[5-(4-methoxy-phenyl)-2- methyl-oxazole-4-carbonyl]-thiazolidin-4-ylmethyl}-amide; θ-Methyl-imidazo^J -bJthiazole-S-carboxylic acid [(R)-3-(4'-methyl-biphenyl-2- carbonyl)-thiazolidin-4-ylmethyl]-amide; 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(3',4'-dimethyl-biphenyl-2- carbonyl)-thiazolidin-4-ylmethyl]-amide; θ-Methyl-imidazo^J -blthiazole-S-carboxylic acid [(R)-3-(3'-methyl-biphenyl-2- carbonyl)-thiazolidin-4-ylmethyl]-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(3'-methoxy-biphenyl-2- carbonyl)-thiazolidin-4-ylmethyl]-amide; θ-Methyl-imidazo^J -blthiazole-S-carboxylic acid [(R)-3-(4'-fluoro-biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide;
6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(4'-methoxy-biphenyl-2- carbonyl)-thiazolidin-4-ylmethyl]-amide; and 6-Methyl-imidazo[2,1 -b]thiazole-5-carboxylic acid [(R)-3-(biphenyl-2-carbonyl)- thiazolidin-4-ylmethyl]-amide; or a pharmaceutically acceptable salt of such a compound.
1 1. A compound of any one of claims 1 to 10, or a pharmaceutically acceptable salt thereof, for use as medicament.
12. Use of a compound according to any of claims 1 to 10, or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of dysthymic disorders including major depression and cyclothymia, affective neurosis, all types of manic depressive disorders, delirium, psychotic disorders, schizophrenia, catatonic schizophrenia, delusional paranoia, adjustment disorders and all clusters of personality disorders; schizoaffective disorders; anxiety disorders including generalized anxiety, obsessive compulsive disorder, posttraumatic stress disorder, panic attacks, all types of phobic anxiety and avoidance; separation anxiety; all psychoactive substance use, abuse, seeking and reinstatement; all types of psychological or physical addictions, dissociative disorders including multiple personality syndromes and psychogenic amnesias; sexual and reproductive dysfunction; psychosexual dysfunction and addiction; tolerance to narcotics or withdrawal from narcotics; increased anaesthetic risk, anaesthetic responsiveness; hypothalamic-adrenal dysfunctions; disturbed biological and circadian rhythms; sleep disturbances associated with diseases such as neurological disorders including neuropathic pain and restless leg syndrome; sleep apnea; narcolepsy; chronic fatigue syndrome; insomnias related to psychiatric disorders; all types of idiopathic insomnias and parasomnias; sleep-wake schedule disorders including jet-lag; all dementias and cognitive dysfunctions in the healthy population and in psychiatric and neurological disorders; mental dysfunctions of aging; all types of amnesia; severe mental retardation; dyskinesias and muscular diseases; muscle spasticity, tremors, movement disorders; spontaneous and medication-induced dyskinesias; neurodegenerative disorders including Huntington's, Creutzfeld-Jacob's, Alzheimer's diseases and Tourette syndrome; Amyotrophic lateral sclerosis; Parkinson's disease; Cushing's syndrome; traumatic lesions; spinal cord trauma; head trauma; perinatal hypoxia; hearing loss; tinnitus; demyelinating diseases; spinal and cranial nerve diseases; ocular damage; retinopathy; epilepsy; seizure disorders; absence seizures, complex partial and generalized seizures; Lennox-Gastaut syndrome; migraine and headache; pain disorders; anaesthesia and analgesia; enhanced or exaggerated sensitivity to pain such as hyperalgesia, causalgia, and allodynia; acute pain; burn pain; atypical facial pain; neuropathic pain; back pain; complex regional pain syndrome I and II; arthritic pain; sports injury pain; dental pain; pain related to infection e.g. by HIV; post-chemotherapy pain; post-stroke pain; post- operative pain; neuralgia; osteoarthritis; conditions associated with visceral pain such as irritable bowel syndrome; eating disorders; diabetes; toxic and dysmetabolic disorders including cerebral anoxia, diabetic neuropathies and alcoholism; appetite, taste, eating, or drinking disorders; somatoform disorders including hypochondriasis; vomiting/nausea; emesis; gastric dyskinesia; gastric ulcers; Kallman's syndrome (anosmia); impaired glucose tolerance; intestinal motility dyskinesias; hypothalamic diseases; hypophysis diseases; hyperthermia syndromes, pyrexia, febrile seizures, idiopathic growth deficiency; dwarfism; gigantism; acromegaly; basophil adenoma; prolactinoma; hyperprolactinemia; brain tumors, adenomas; benign prostatic hypertrophy, prostate cancer; endometrial, breast, colon cancer; all types of testicular dysfunctions, fertility control; reproductive hormone abnormalities; hot flashes; hypothalamic hypogonadism, functional or psychogenic amenorrhea; urinary bladder incontinence; asthma; allergies; all types of dermatitis, acne and cysts, sebaceous gland dysfunctions; cardiovascular disorders; heart and lung diseases, acute and congestive heart failure; hypotension; hypertension; dyslipidemias, hyperlipidemias, insulin resistance; urinary retention; osteoporosis; angina pectoris; myocardial infarction; arrhythmias, coronary diseases, left ventricular hypertrophy; ischemic or haemorrhagic stroke; all types of cerebrovascular disorders including subarachnoid haemorrhage, ischemic and hemorrhagic stroke and vascular dementia; chronic renal failure and other renal diseases; gout; kidney cancer; urinary incontinence; and other diseases related to general orexin system dysfunctions.
13. Use of a compound according to any of claims 1 to 10, or of a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the prevention or treatment of diseases selected from the group consisting of all types of sleep disorders, of stress-related syndromes, of psychoactive substance use and abuse, of cognitive dysfunctions in the healthy population and in psychiatric and neurologic disorders, of eating or drinking disorders.
PCT/IB2008/051110 2007-03-26 2008-03-25 Thiazolidine derivatives as orexin receptor antagonists WO2008117241A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
JP2010500407A JP2010522737A (en) 2007-03-26 2008-03-25 Thiazolidine derivatives as orexin receptor antagonists
BRPI0808504-8A BRPI0808504A2 (en) 2007-03-26 2008-03-25 TIAZOLIDINE DERIVATIVE COMPOUND AND USE
AU2008231441A AU2008231441A1 (en) 2007-03-26 2008-03-25 Thiazolidine derivatives as orexin receptor antagonists
CN2008800096488A CN101641342B (en) 2007-03-26 2008-03-25 Thiazolidine derivatives as orexin receptor antagonist
MX2009009690A MX2009009690A (en) 2007-03-26 2008-03-25 Thiazolidine derivatives as orexin receptor antagonists.
EP08719826A EP2125760A2 (en) 2007-03-26 2008-03-25 Thiazolidine derivatives as orexin receptor antagonists
US12/593,095 US8236964B2 (en) 2007-03-26 2008-03-25 Thiazolidine derivatives as orexin receptor antagonists
CA002677991A CA2677991A1 (en) 2007-03-26 2008-03-25 Thiazolidine derivatives
IL201112A IL201112A0 (en) 2007-03-26 2009-09-23 Thiazolidine derivatives as orexin receptor antagonists
MA32243A MA31289B1 (en) 2007-03-26 2009-10-02 THIAZOLIDINE DERIVATIVES
NO20093200A NO20093200L (en) 2007-03-26 2009-10-23 thiazolidine derivatives

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IBPCT/IB2007/051048 2007-03-26
IB2007051048 2007-03-26
IB2008050620 2008-02-21
IBPCT/IB2008/050620 2008-02-21

Publications (2)

Publication Number Publication Date
WO2008117241A2 true WO2008117241A2 (en) 2008-10-02
WO2008117241A3 WO2008117241A3 (en) 2008-12-31

Family

ID=39789108

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2008/051110 WO2008117241A2 (en) 2007-03-26 2008-03-25 Thiazolidine derivatives as orexin receptor antagonists

Country Status (17)

Country Link
US (1) US8236964B2 (en)
EP (1) EP2125760A2 (en)
JP (1) JP2010522737A (en)
KR (1) KR20090125195A (en)
CN (1) CN101641342B (en)
AR (1) AR065822A1 (en)
AU (1) AU2008231441A1 (en)
BR (1) BRPI0808504A2 (en)
CA (1) CA2677991A1 (en)
CL (1) CL2008000836A1 (en)
IL (1) IL201112A0 (en)
MA (1) MA31289B1 (en)
MX (1) MX2009009690A (en)
NO (1) NO20093200L (en)
RU (1) RU2009139285A (en)
TW (1) TW200901988A (en)
WO (1) WO2008117241A2 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010004507A1 (en) * 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
CN102414184A (en) * 2009-05-12 2012-04-11 埃科特莱茵药品有限公司 Novel oxazolidinone derivatives and their use as orexin receptor antagonists
WO2013182972A1 (en) 2012-06-04 2013-12-12 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014141065A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
WO2015083071A1 (en) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
WO2015083094A1 (en) 2013-12-04 2015-06-11 Actelion Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
WO2015083070A1 (en) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
US9133204B2 (en) 2007-07-19 2015-09-15 H. Lundbeck A/S 5-membered heterocyclic amides and related compounds
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9499517B2 (en) 2012-02-07 2016-11-22 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
US10828302B2 (en) 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US11059828B2 (en) 2009-10-23 2021-07-13 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE481383T1 (en) * 2006-09-29 2010-10-15 Actelion Pharmaceuticals Ltd 3-AZA-BICYCLOÄ3.1.0ÜHEXANE DERIVATIVES
DE602007012142D1 (en) 2006-12-01 2011-03-03 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
CL2007003827A1 (en) * 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM N- (2-AZA-BICYCLE (3.1.0) HEX-3-ILMETIL) AMIDA; AND ITS USE TO PREVENT OR TREAT DEPRESSION, NEUROSIS, SCHIZOPHRENIA, ANXIETY, ADDICTIONS, EPILEPSY, PAIN, HEART DISEASES, AMONG OTHERS.
US8288429B2 (en) * 2007-07-27 2012-10-16 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[3.3.0]octane derivatives
WO2009040730A2 (en) * 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
MX2010008993A (en) * 2008-02-21 2010-09-07 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives.
WO2009133522A1 (en) * 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
KR20110071004A (en) * 2008-10-14 2011-06-27 액테리온 파마슈티칼 리미티드 Phenethylamide derivatives and their heterocyclic analogues
CA2815179A1 (en) * 2010-11-10 2012-05-18 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
RU2643583C1 (en) * 2016-10-24 2018-02-02 Федеральное государственное бюджетное образовательное учреждение высшего образования "Уральский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО УГМУ Минздрава России) Method for treatment of chronic pain syndromes, formed on basis of post-traumatic stress disorder, combined with combat brain injury effects

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096302A1 (en) * 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines for use as orexin receptor antagonists
WO2002044172A1 (en) * 2000-11-28 2002-06-06 Smithkline Beecham P.L.C. Morpholine derivatives as antagonists of orexin receptors
WO2003032991A1 (en) * 2001-10-11 2003-04-24 Smithkline Beecham Plc N-aroyl piperazine derivatives as orexin receptor antagonists
WO2004041816A1 (en) * 2002-11-06 2004-05-21 Glaxo Group Limited Azacyclic compounds as orexin receptor antagonist

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57139032A (en) 1981-02-20 1982-08-27 Takasago Corp 2-(butan-2-on-3-yl)-5-methylphenol and perfumery composition containing the same
BR0209334A (en) 2001-05-05 2004-06-15 Smithkline Beecham Plc Cyclic n-aroil amines
US20040192673A1 (en) * 2001-05-05 2004-09-30 Pascale Gaillard N-aroyl cyclic amine derivatives as orexin receptor antagonists
ES2266549T3 (en) 2001-06-28 2007-03-01 Smithkline Beecham Plc CYCLIC N-AROIL-AMINA DERIVATIVES AS AN OREXINE RECEIVER ANTAGONISTS.
GB0115862D0 (en) 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0127145D0 (en) 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130393D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
GB0130335D0 (en) 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
AU2003262516A1 (en) 2002-09-18 2004-04-08 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
GB0225938D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225944D0 (en) 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
HUP0304101A3 (en) * 2003-12-22 2008-10-28 Sanofi Aventis Pyrazole derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
CN103724343A (en) 2004-03-25 2014-04-16 记忆药物公司 Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
US20060014733A1 (en) 2004-07-19 2006-01-19 Pfizer Inc Histamine-3 agonists and antagonists
US20070060589A1 (en) 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
CN101506199A (en) * 2006-08-15 2009-08-12 埃科特莱茵药品有限公司 Azetidine compounds as orexin receptor antagonists
ATE481383T1 (en) * 2006-09-29 2010-10-15 Actelion Pharmaceuticals Ltd 3-AZA-BICYCLOÄ3.1.0ÜHEXANE DERIVATIVES
DE602007012142D1 (en) * 2006-12-01 2011-03-03 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino bzw. amido)-1- (biphenyl bzw. phenylthiazolyl) carbonylpiperdinderivate als orexinrezeptor-inhibitoren
CL2007003827A1 (en) * 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd COMPOUNDS DERIVED FROM N- (2-AZA-BICYCLE (3.1.0) HEX-3-ILMETIL) AMIDA; AND ITS USE TO PREVENT OR TREAT DEPRESSION, NEUROSIS, SCHIZOPHRENIA, ANXIETY, ADDICTIONS, EPILEPSY, PAIN, HEART DISEASES, AMONG OTHERS.
DE602008002934D1 (en) * 2007-05-14 2010-11-18 Actelion Pharmaceuticals Ltd 2-CYCLOPROPYLTHIAZOLDERIVATE
UA99620C2 (en) * 2007-05-23 2012-09-10 Мерк Шарп Энд Доме Корп. Pyridyl piperidine orexin receptor antagonists
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
EP2164847B1 (en) * 2007-07-03 2011-09-14 Actelion Pharmaceuticals Ltd. 3-aza-bicyclo[3.3.0]octane compounds
AR067665A1 (en) * 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd DERIVATIVES OF TRANS-3- AZA-BICYCLE (3.1.0) HEXANO
US8288429B2 (en) * 2007-07-27 2012-10-16 Actelion Pharmaceuticals Ltd. 2-aza-bicyclo[3.3.0]octane derivatives
WO2009040730A2 (en) * 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
MX2010008993A (en) * 2008-02-21 2010-09-07 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[2.2.1]heptane derivatives.
WO2009133522A1 (en) * 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001096302A1 (en) * 2000-06-16 2001-12-20 Smithkline Beecham P.L.C. Piperidines for use as orexin receptor antagonists
WO2002044172A1 (en) * 2000-11-28 2002-06-06 Smithkline Beecham P.L.C. Morpholine derivatives as antagonists of orexin receptors
WO2003032991A1 (en) * 2001-10-11 2003-04-24 Smithkline Beecham Plc N-aroyl piperazine derivatives as orexin receptor antagonists
WO2004041816A1 (en) * 2002-11-06 2004-05-21 Glaxo Group Limited Azacyclic compounds as orexin receptor antagonist

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAI J ET AL: "Antagonists of the orexin receptors" EXPERT OPINION ON THERAPEUTIC PATENTS, INFORMA HEALTHCARE, GB, vol. 16, no. 5, 1 May 2006 (2006-05-01), pages 631-646, XP002458093 ISSN: 1354-3776 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133204B2 (en) 2007-07-19 2015-09-15 H. Lundbeck A/S 5-membered heterocyclic amides and related compounds
WO2010004507A1 (en) * 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
CN102414184A (en) * 2009-05-12 2012-04-11 埃科特莱茵药品有限公司 Novel oxazolidinone derivatives and their use as orexin receptor antagonists
US11667644B2 (en) 2009-10-23 2023-06-06 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
USRE48841E1 (en) 2009-10-23 2021-12-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US11059828B2 (en) 2009-10-23 2021-07-13 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-C]pyrroles as orexin receptor modulators
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9896452B2 (en) 2012-02-07 2018-02-20 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
US9499517B2 (en) 2012-02-07 2016-11-22 Eolas Therapeutics, Inc. Substituted prolines / piperidines as orexin receptor antagonists
US11040966B2 (en) 2012-06-04 2021-06-22 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
US9732075B2 (en) 2012-06-04 2017-08-15 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2013182972A1 (en) 2012-06-04 2013-12-12 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
US10329287B2 (en) 2012-06-04 2019-06-25 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
WO2014057435A1 (en) 2012-10-10 2014-04-17 Actelion Pharmaceuticals Ltd Orexin receptor antagonists which are [ortho bi (hetero )aryl]-[2-(meta bi (hetero )aryl)-pyrrolidin-1-yl]-methanone derivatives
WO2014141065A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
WO2015083071A1 (en) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
US9790208B2 (en) 2013-12-03 2017-10-17 Idorsia Pharmaceuticals Ltd Crystalline salt form of (S)-(2-(6-chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
WO2015083070A1 (en) 2013-12-03 2015-06-11 Actelion Pharmaceuticals Ltd Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
US9914720B2 (en) 2013-12-03 2018-03-13 Idorsia Pharmaceuticals Ltd Crystalline form of (S)-(2-(6-chloro-7-methyl-1H-benzo[D]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
US10023560B2 (en) 2013-12-03 2018-07-17 Idorsia Pharmaceuticals Ltd Crystalline salt form of (S)-(2-(6 chloro-7-methyl-1H-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
US9914721B2 (en) 2013-12-04 2018-03-13 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
WO2015083094A1 (en) 2013-12-04 2015-06-11 Actelion Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
US10221170B2 (en) 2014-08-13 2019-03-05 Eolas Therapeutics, Inc. Difluoropyrrolidines as orexin receptor modulators
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US11434236B2 (en) 2016-02-12 2022-09-06 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US12084437B2 (en) 2016-02-12 2024-09-10 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US10828302B2 (en) 2016-03-10 2020-11-10 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
US11241432B2 (en) 2016-03-10 2022-02-08 Janssen Pharmaceutica Nv Methods of treating depression using orexin-2 receptor antagonists
WO2017194548A1 (en) 2016-05-10 2017-11-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory diseases
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
WO2023218023A1 (en) 2022-05-13 2023-11-16 Idorsia Pharmaceuticals Ltd Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives

Also Published As

Publication number Publication date
TW200901988A (en) 2009-01-16
AR065822A1 (en) 2009-07-01
CN101641342B (en) 2012-10-03
NO20093200L (en) 2009-10-23
CA2677991A1 (en) 2008-10-02
AU2008231441A1 (en) 2008-10-02
EP2125760A2 (en) 2009-12-02
JP2010522737A (en) 2010-07-08
BRPI0808504A2 (en) 2014-08-19
US20100113531A1 (en) 2010-05-06
CL2008000836A1 (en) 2008-11-07
IL201112A0 (en) 2010-05-17
RU2009139285A (en) 2011-05-10
MA31289B1 (en) 2010-04-01
WO2008117241A3 (en) 2008-12-31
CN101641342A (en) 2010-02-03
US8236964B2 (en) 2012-08-07
MX2009009690A (en) 2009-12-14
KR20090125195A (en) 2009-12-03

Similar Documents

Publication Publication Date Title
US8236964B2 (en) Thiazolidine derivatives as orexin receptor antagonists
EP2069332B1 (en) Azetidine compounds as orexin receptor antagonists
EP2164847B1 (en) 3-aza-bicyclo[3.3.0]octane compounds
EP2155739B1 (en) 2-cyclopropyl-thiazole derivatives
EP2185512B1 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
EP2188282B1 (en) 1,2-diamido-ethylene derivatives as orexin antagonists
US8063099B2 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
EP2247586A1 (en) 2-aza-bicyclo[2.2.1]heptane derivatives
WO2009040730A2 (en) Pyrrolidines and piperidines as orexin receptor antagonists
WO2010038200A1 (en) Oxazolidine compounds as orexin receptor antagonists
WO2009016564A2 (en) 2-aza-bicyclo[3.3.0]octane derivatives
WO2010004507A1 (en) Thiazolidine compounds as orexin receptor antagonists
WO2008087611A2 (en) Pyrrolidine- and piperidine- bis-amide derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880009648.8

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2008719826

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2677991

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009081251

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/009690

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12009501809

Country of ref document: PH

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08719826

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 201112

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2010500407

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 12593095

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 580528

Country of ref document: NZ

Ref document number: 2008231441

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 20097022153

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 6276/CHENP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009139285

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0808504

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090904